

References

- Achan V, Broadhead M, Malaki M, Whitley G, Leiper J, Mac Allister R, Vallance P:** Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase. *Arterioscler Thromb Vasc Biol* 23: 1455–1459, **2003**
- Achmad TH, Rao GS:** Chemotaxis of human blood monocytes toward endothelin-1 and the influence of calcium channel blockers. *Biochem Biophys Res Commun* 189: 994–1000, **1992**
- Aicher A, Heeschen C, Mildner-Rihm C, Urbich C, Ihling C, Technau-Ihling K, Zeiher AM, Dimmeler S:** Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells. *Nat Med* 9: 1370–1376, **2003**
- Alexander BT, Llinas MT, Kruckeberg WC, Granger JP:** L Arginine attenuates hypertension in pregnant rats with reduced uterine perfusion pressure. *Hypertension* 43:832-6, **2004**
- Anderson TJ, Elstein E, Haber H, et al.** Comparative study of ACE inhibition, angiotensin II antagonism, and calcium channel blockade on flow-mediated vasodilation in patients with coronary disease (BANFF study). *J Am Coll Cardiol.* 35:60–66, **2000**
- Andrew PJ, Mayer B.** Enzymatic function of nitric oxide synthases. *Cardiovasc Res* 43: 521–531, **1999**
- Annuk M, Zilmer M, Lind L, Linde T, Fellstrom B:** Oxidative stress and endothelial function in chronic renal failure. *J Am Soc Nephrol* 12: 2747–2752, **2001**
- Arai H, Hori S, Aramori I, Ohkubo H, Nakanishi S:** Cloning and expression of a cDNA encoding an endothelin receptor. *Nature* 348: 730–732, **1990**

- Axelsson J, Witasp A, Carrero JJ, Qureshi AR, Suliman M, Heimbürger O, Barany P, Lindholm B, Alvestrand A, Schalling M, Nordfors L, Stenvinkel P:** Circulating levels of visfatin/Pre-B-Cell colony-enhancing factor 1 in relation to genotype GFR, body composition, and survival in patients with CKD. *Am J Kidney Dis* 49: 237–244, **2007**
- Aymong ED, Curtis MJ, Youssef M, et al.** Abciximab attenuates coronary microvascular endothelial dysfunction after coronary stenting. *Circulation* 105:2981–2985, **2002**
- Barleon B, Sozzani S, Zhou D, Weich HA, Mantovani A, Marme D:** Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. *Blood* 90: 1365–1372, **1997**
- Bartalena L, Brogioni S, Grasso L, Velluzzi F, Martino E:** Relationship of the increased serum interleukin-6 concentration to changes of thyroid function in nonthyroidal illness. *J Endocrinol Invest* 17: 269–274, **1994**
- Bartalena L:** The dilemma of non-thyroidal illness syndrome: To treat or not to treat? *J Endocrinol Invest* 26: 1162, **2003**
- Bassuk J, Pichler R, Rothmeier JD, Pippen J, Gordon K, Meek R, Bradshaw A, Lombardi D, Strandjord T, Reed M, Sage EH, Couser WG, Johnson RJ:** Induction of TGF- β by the matrix cellular protein SPARC in a rat model of glomerulonephritis. *Kidney Int* 57: 117–128, **2000**
- Behrendt D, Ganz P.** Endothelial function: from vascular biology to clinical applications. *Am J Cardiol* 90(suppl):40L–48L, **2002**
- Bello-Reuss E, Holubec K, Rajaraman S:** Angiogenesis in autosomal dominant polycystic kidney disease. *Kidney Int* 60: 37–45, **2001**
- Benigni A, Perico N, Ladny J et al.** Increased urinary excretion of endothelin-1 and its precursor, big-endothelin, in rats chronically treated with cyclosporine. *Transplantation* 52: 175–77, **1990**
- Benigni A:** Defining the role of endothelins in renal pathophysiology on the basis of selective and unselective endothelin receptor antagonist studies. *Curr Opin Nephrol Hypertens* 4: 349–353, **1995**

- Bennett-Richards K, Kattenhorn M, Donald A, Oakley G, Varghese Z, Rees L, Deanfield JE:** Does oral folic acid lower total homocysteine levels and improve endothelial function in children with chronic renal failure? *Circulation* 105: 1810–1815, 2002
- Berse B, Brown LF, van der Water L, Dvorak HF, Senger DR:** Vascular permeability factor (VEGF) gene is expressed differentially in normal tissues, macrophages, and tumors. *Mol BiolCell* 3: 211–220, 1992
- Bird E, Giancarli M, Burton D, Durham S.** Endothelin-A receptors mediate ET effects in radiocontrast nephropathy. *J Am Soc Nephrol* 6: 994 (abstr), 1995
- Blacher J, Guerin AP, Pannier B, Marchais SJ, Safar ME, London GM:** Impact of aortic stiffness on survival in end stage renal disease. *Circulation* 99: 2434–2439, 1999
- Blacher J, Guerin AP, Pannier B, Marchais SJ, London GM:** Arterial calcifications, arterial stiffness and cardiovascular risk in end-stage renal disease. *Hypertension* 38: 938–942, 2001
- Block GA, Hulbert-Shearon TE, Levin NW, Port FK:** Association of serum phosphorus and calcium _ phosphate product with mortality risk in chronic hemodialysis patients: A national study. *Am J Kidney Dis* 31: 607–617, 1998
- Block GA, Spiegel DM, Ehrlich J, Mehta R, Lindbergh J, Dreisbach A, Raggi P:** Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. *Kidney Int* 68: 1815–1824, 2005
- Blokhina O, Virolainen E, Fagerstedt KV.** Antioxidants, oxidative damage and oxygen deprivation stress: a review. *Ann Bot (Lond)* 91: 179–194, 2003
- Boaz M, matas Z, Biro A, Katzir Z, Green M, Fainaru M, Smetana S:** Serum malonaldehyde and prevalent cardiovascular disease in hemodialysis. *Kidney Int* 56: 1978–1983, 1999

- Boaz M, Smetana S, Weinstein T, Matas Z, Gafter U, Iaina A, Knecht A, Weissgarten Y, Brunner D, Fainaru M, Green MS:** Secondary prevention with antioxidants of cardiovascular disease in end stage renal disease (SPACE): Randomised placebo-controlled trial. *Lancet* 356: 1213–1218, **2000**
- Boehme M, Kaehne F, Kuehne A, Bernhardt W, Schroder M, Pommer W, Fischer C, Becker H, Muller C, Schindler R:** Pentraxin 3 is elevated in haemodialysis patients and is associated with cardiovascular disease. *Nephrol Dial Transplant* 22: 2224–2229, **2007**
- Boffa JJ, Tharaux PL, Dussaule JC, Chatziantoniou C:** Regression of renal vascular fibrosis by endothelin receptor antagonism. *Hypertension* 37: 490–496, **2001**
- Boger RH, Lentz SR, Bode-Boger SM, Knapp HR, Haynes WG:** Elevation of asymmetrical dimethylarginine may mediate endothelial dysfunction during experimental hyperhomocyst(e)inaemia in humans. *Clin Sci (Lond)* 100: 161–167, **2001**
- Boger RH, Schwedhelm E, Maas R, Quispe-Bravo S, Skamira C:** ADMA and oxidative stress may relate to the progression of renal disease: rationale and design of the VIVALDI study. *Vasc Med* 10 (Suppl 1): S97-102, **2005**
- Bohle A, Mackensen-Haen S, Wehrmann M:** Significance of post-glomerular capillaries in the pathogenesis of chronic renal failure. *Kidney Blood Press Res* 19: 191–195, **1996**
- Bolton CH, Downs LG, Victory JGG, Dwight JF, Tomson CRV, Mackness MI, Pinkney JH:** Endothelial dysfunction in chronic renal failure: Roles of lipoprotein oxidation and pro-inflammatory cytokines. *Nephrol Dial Transpl* 16: 1189–1197, **2001**
- Bonetti PO, Lerman LO, Lerman A:** Endothelial dysfunction: A marker of atherosclerotic risk. *Arterioscler Thromb Vasc Biol* 23: 168–175, **2003**
- Border WA, Noble NA:** Transforming growth factor-beta in tissue fibrosis. *N Engl J Med* 331: 1286–1292, **1994**

- Braun J, Oldendorf M, Moshage W, Heidler F, Zeitler E, Luft FC:** Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients. *Am J Kidney Dis* 27: 394–401, 1996
- Breiteneder-Geleff S, Soleiman A, Kowalski J, Horvat R, Amann G, Kriehuber E, Diem K, Weninger W, Tschachler E, Alitalo K, Kerjaschki D:** Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries. Podoplanin as a specific marker of lymphatic endothelium. *Am J Pathol* 154: 385–394, 1999
- Brenner BM, Meyer TW, Hostetter TH:** Dietary protein intake and the progressive nature of kidney disease: the role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease. *N Engl J Med* 307: 652–659, 1982
- BM, Garcia DL, Anderson S.** Glomeruli and blood pressure. Less of one, more the other? *Am J Hypertens* 1: 335–47, 1988
- Brochu E, Lacasse S, Moreau C, Lebel M, Kingma I, Grose JH, Lariviere R:** Endothelin ET (A) receptor blockade prevents the progression of renal failure and hypertension in uraemic rats. *Nephrol Dial Transplant* 14: 1881–1888, 1999
- Brodsky S, GaliKman O, Chen J, et al:** Prevention and reversal of premature endothelial cell senescence and vasculopathy in obesity-induced diabetes by ebselen. *Circ Res* 94:377–384, 2004
- Brooks DP, DePalma PD, Gellai M, et al.** Nonpeptide endothelin receptor antagonists. III. Effect of SB 209670 and BQ123 on acute renal failure in anesthetized dogs. *J Pharmacol Exp Ther* 271:1–7, 1994
- Bruzzi I, Benigni A, Remuzzi G:** Role of increased glomerula protein traffic in the progression of renal failure. *Kidney Int* 62 [Suppl]: S29–S31, 1997
- Butler R, Morris AD, Belch JJ, et al:** Allopurinol normalizes endothelial dysfunction in type 2 diabetics with mild hypertension. *Hypertension* 35:746–751, 2000

- Cano NJ, Fouque D, Roth H, Aparicio M, Azar R, Canaud B, Chauveau P, Combe C, Laville M, and Leverve XM:** Intradialytic parenteral nutrition does not improve survival in malnourished hemodialysis patients: A 2-year multicenter, prospective, randomized study. *J Am Soc Nephrol* 18: 2583–2591, 2007
- Carrero JJ, Qureshi AR, Axelsson J, Yilmaz MI, Rehnmar kS, Witt MR, Barany P, Heimbürger O, Suliman ME, Alvestrand A, Lindholm B, Stenvinkel P:** Clinical and biochemical implications of low thyroid hormone levels (total and free forms) in euthyroid patients with chronic kidney disease. *J Int Med* 262: 690–701, 2007
- Carrero JJ, Stenvinkel P, Fellstrom B, Qureshi AR, Lamb K, Heimbürger O, Barany P, Radhakrishnan K, Lindholm B, Soveri I, Nordfors L, Shiels P:** Telomere attrition is associated to inflammation, low fetuin-A levels and high mortality in prevalent hemodialysis patients. *J Int Med* 2008
- Casas JP, Shah T, Cooper J, Haw E, McMahon AD, Gaffney D, Packard CJ, O'Reilly DS, Juhan-Vague I, Yudkin JS, Tremoli E, Margaglione M, Di Minno G, Hamsten A, Kooistra T, Stephens JW, Hurel SJ, Livingstone S, Colhoun HM, Miller GJ, Bautista LE, Meade T, Sattar N, Humphries SE, Hingorani AD:** Insight into the nature of the CRP-coronary event association using Mendelian randomization. *Int Epidemiol* 35: 922–931, 2006
- Cashin Hemphill L, Holmvang G, Chan RC, et al:** Angiotensin-converting enzyme inhibition as antiatherosclerotic therapy: No answer yet. QUIET Investigators. QUinapril Ischemic Event Trial. *Am J Cardiol* 83:43–47, 1999
- Castilla P, Da'valos A, Teruel JL et al.** Comparative effects of dietary supplementation with red grape juice and vitamin E on production of superoxide by circulating neutrophil NADPH oxidase in hemodialysis patients. *Am J Clin Nutr* 87: 1053–1061, 2008
- Castro R, Rivera I, Struys EA, Jansen EEW, Ravasco P, Camilo ME, Blom HJ, Jakobs C, De Almeida IT:** Increased homocysteine and S-adenosylhomocysteine concentrations and DNA hypomethylation in vascular disease. *Clin Chem* 49: 1292–1296, 2003

- Catravas J, Lazo J, Dobuler K, et al:** Pulmonary endothelial dysfunction in the presence or absence of interstitial injury induced by intratracheally injected bleomycin in rabbits. *Am Rev Resp Dis* 128:740–746, **1983**
- Celermajer DS, Sorensen KE, Bull C, et al.** Endothelium-dependent dilation in the systemic arteries of asymptomatic subjects relates to coronary risk factors and their interactions. *J Am Coll Cardiol.* 24: 1468–1474, **1994**
- Cernacek P, Stewart DJ:** Immunoreactive endothelin in human plasma: Marked elevations in patients in cardiogenic shock. *Biochem Biophys Res Commun* 161: 562–567, **1989**
- Chen HC, Guh JY, Chang JM, Tsai JC, Hwang SJ, Lai YH:** Plasma and urinary endothelin-1 in focal segmental glomerulosclerosis. *J Clin Lab Anal* 15: 59–63, **2001**
- Chen X, Touyz RM, Park JB, Schiffrin EL:** Antioxidant effects of vitamins C and E are associated with altered activation of vascular NADPH oxidase and superoxide dismutase in stroke prone SHR. *Hypertension* 38: 606–611, **2001**
- Chen J, Brodsky S, Hampel D, et al:** Delayed branching of endothelial capillary cords in glycated collagen I is mediated by the early induction of PAI-1. *Am J Physiol* 281:F71–F80, **2001**
- Chen J, Brodsky S, Goligorsky DM, et al:** Glycated collagen I induces premature senescence-like phenotypic changes in endothelial cells. *Circ Res* 90:1290–1298, **2002**
- Chen NX, Moe SM:** Vascular calcification in chronic kidney disease. *Semin Nephrol* 24: 61–68, **2004**
- Chertow GM, Goldstein-Fuchs DJ, Lazarus JM, Kaysen GA:** Prealbumin, mortality, and cause-specific hospitalization in hemodialysis patients. *Kidney Int* 68: 2794–2800, **2005**
- Chiang CK, Hsu SP, Pai MF, Peng YS, Ho TI, Liu SH, Hung KY, Tsai TJ:** Interleukin-18 is a strong predictor of hospitalization in haemodialysis patients. *Nephrol Dial Transpl* 19: 2810–2815, **2004**

- Choi YJ, Chakraborty S, Nguyen V, Nguyen C, Kim BK, Shim SI, Suki WN, Truong LD:** Peritubular capillary loss is associated with chronic tubulointerstitial injury in human kidney: Altered expression of vascular endothelial growth factor. *Hum Pathol* 31:1491–1497, **2000**
- Chopra IJ:** Nonthyroidal illness syndrome or euthyroid sick syndrome? *Endocr Pract* 2: 45–52, **1996**
- Civilibal M, Caliskan S, Adaletli I, Oflaz H, Sever L, Candan C, Canpolat N, Kasapcopur O, Kuruoglu S, Arisoy N:** Coronary artery calcifications in children with end-stage renal disease. *Pediatr Nephrol* 21: 1426–1433, **2006**
- Clausen P, Jensen JS, Jensen G, Borch-Johnsen K, Feldt Rasmussen B:** Elevated urinary albumin excretion is associated with impaired arterial dilatory capacity in clinically healthy subjects. *Circulation* 103: 1869–1874, **2001**
- Cooper ME, Vranes D, Youssef S, Stacker SA, Cox AJ, Rizkalla B, Casley DJ, Bach LA, Kelly DJ, Gilbert RE:** Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes. *Diabetes* 48: 2229–2239, **1999**
- Corretti MC, Anderson TJ, Benjamin EJ, et al.** Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. *J Am Coll Cardiol.* 39:257–265, **2002**
- Cross JM, Donald AE, Kharbanda R, Deanfield JE, Woolfson RG, Macallister RJ:** Acute administration of L-arginine does not improve arterial endothelial function in chronic renal failure. *Kidney Int* 60: 2318–2323, **2001**
- Cross JM, Donald AE, Nuttall SL, Deanfield JE, Woolfson RG, Macallister RJ:** Vitamin C improves resistance but not conduit artery endothelial function in patients with chronic renal failure. *Kidney Int* 63: 1433–1442, **2003**
- Day JK, Bauer AM, desBordes C, Zhuang Y, Kim B-E, Newton LG, Nehra V, Forsee KM, Mac Donald RS, Besch-Williford C, Huang TH, Lubahn DB:** Genistein alters methylation patterns in mice. *J Nutr* 132: 2419S–2423S, **2002**

- Dayoub H, Achan V, Adimoolam S, Jacobi J, Stuehlinger MC, Wang BY, Tsao PS, Kimoto M, Vallance P, Patterson AJ, Cooke JP:** Dimethylarginine dimethylaminohydrolase regulates nitric oxide synthesis: genetic and physiological evidence. *Circulation* 108: 3042–3047, **2003**
- De Mutsert R, Snijder MB, van der Sman-de Beer F, Seidell JC, Boeschoten EW, Krediet RT, Dekker JM, Vandenbroucke JP, Dekker FW:** The association between body mass index and mortality is similar in the hemodialysis population and the general population at high age and equal duration of follow-up. *J Am Soc Nephrol* 18: 967–974, **2007**
- Deanfield J, Donald A, Ferri C et al.** Endothelial function and dysfunction: Part I. Methodological issues for assessment in the different vascular beds: a statement by the Working Group on Endothelin and Endothelial Factors of the European Society of Hypertension. *J Hypertens* 23: 7–17, **2005**
- Deray G, Carayon A, Maistre G, Benhmida M, Masson F, Barthelemy C, Petitclerc T, Jacobs C:** Endothelin in chronic renal failure. *Nephrol Dial Transplant* 7: 300–305, **1992**
- Devaraj S, Xu DY, Jialal I.** C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis. *Circulation*. 107:398–404, **2003**
- Diep QN, Amiri F, Touyz RM, Cohn JS, Endemann D, Neves MF, Schiffrin EL:** PPAR_γ activator effects on Ang II-induced vascular oxidative stress and inflammation. *Hypertension* 40:866–871, **2002**
- Diep QN, El Mabrouk M, Cohn JS, Endemann D, Amiri F, Virdis A, Neves MF, Schiffrin EL:** Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensinII-infused rats: Role of peroxisome proliferator-activatedreceptor-gamma. *Circulation* 105: 2296–2302, **2002**
- Diepeveen SH, Wetzels JF, Bilo HJ et al.** Cholesterol in end-stage renal disease: the good, the bad or the ugly? *Neth J Med* 66: 53–61, **2008**

- Diercks GF, Stroes ES, van Boven AJ, van Roon AM, Hillege HL, de Jong PE, Smit AJ, Gans RO, Crijns HJ, Rabelink TJ, Van-Gilst WH:** Urinary albumin excretion is related to cardiovascular risk indicators, not to flow-mediated vasodilation, in apparently healthy subjects. *Atherosclerosis* 163: 121–126, **2002**
- Dierk H, Endemann , Ernestol, Schiffrin:** Endothelial Dysfunction
Am J Soc Nephrol 15:1983–1992, **2004**
- Dijkhorst-Oei LT, Stroes ESG, Koomans HA, Rabelink TJ** Acute simultaneous stimulation of nitric oxide and oxygen radicals: Am J Cardiol 83:43–47, **1999**
- DiPietro LA, Polverine PJ:** Angiogenic macrophages produce the angiogenic inhibitor thrombospondin 1. *Am J Pathol* 143: 678–684, **1993**
- Dobashi K, Ghosh B, Orak JK et al.** Kidney ischemia-reperfusion: modulation of antioxidant defenses. *Mol Cell Biochem* 205: 1–11, **2000**
- Doehner W, Schoene N, Rauchaus M, et al:** Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: Results from 2 placebo-controlled studies. *Circulation* 105:2619–2624, **2002**
- Dogra GK, Watts GF, Herrmann S, Thomas MA, Irish AB:** Statin therapy improves brachial artery endothelial function in nephrotic syndrome. *Kidney Int* 62: 550–557, **2002**
- Dong C, Yoon W, Goldsmith-Clermont PJ:** DNA methylation and atherosclerosis. *J Nutr* 132: 2406S–2409S, **2002**
- Dounousi E, Papavasiliou E, Makedou A et al.** Oxidative stress is progressively enhanced with advancing stages of CKD. *Am J Kidney Dis* 48: 752–760, **2006**
- Douyon L, Schteingart DE:** Effect of obesity and starvation on thyroid hormone, growth hormone, and cortisol secretion. *Endocrinol Metab Clin North Am* 31: 173–189, **2002**
- Drexler H.** Factors involved in the maintenance of endothelial function. *Am J Cardiol.* 82:3S–4S , **1998**

- Drueke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, Burger HU, Scherhag A:** Normalization of hemoglobin level in patients with chronic kidney disease and anemia. *N Engl J Med* 355: 2071–2084, **2006**
- Du X, Matsumura T, Edelstein D, Rossetti L, Zsengeller Z, Szabo C, Brownlee M:** Inhibition of GAPDH activity by poly- (ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells. *J Clin Invest* 112: 1049–1057, **2003**
- Duh E, Aiello LP:** Vascular endothelial growth factor and diabetes: The agonist versus antagonist paradox. *Diabetes* 48:1899–1906, **1999**
- Eddy A:** Role of cellular infiltrates in response to proteinuria. *Am J Kidney Dis* 37[Suppl]: S25–S29, **2001**
- Edmond O’Riordan, Jun Chen, Sergey V. Brodsky, Iva Smirnova, Hong Li, and Michael S. Goligorsky :** Endothelial cell dysfunction ,The syndrome in making . *Kidney International*, Vol.67, pp.1654n1658, **2005**
- Eknoyan G, Beck GJ, Cheung AK, Daugirdas JT, Greene T, Kusek JW, Allon M, Bailey J, Delmez JA, Depner TA, Dwyer JT, Levey AS, Levin NW, Milford E, Ornt DB, Rocco MV, Schulman G, Schwab SJ, Teehan BP, Toto R:** Effect of dialysis dose and membrane flux in maintenance hemodialysis. *N Engl J Med* 347: 2010–2019, **2002**
- El-Abbadi M, Giachelli CM:** Mechanisms of vascular calcification. *Adv Chronic Kidney Dis* 14: 54–66, **2007**
- Elsayed EF, Tighiouart H, Griffith J, Kurth T, Levey A, Salem D, Sarnak MJ, Weiner DE:** Cardiovascular disease and subsequent kidney disease. *Arch Intern Med* 167: 1130–1136, **2007**
- Enia G, Panuccio V, Cutrupi S, Pizzini P, Tripepi G, Mallamaci F, Zoccali C:** Subclinical hypothyroidism is linked to micro-inflammation and predicts death in continuous ambulatory peritoneal dialysis. *Nephrol Dial Transplant* 22:538–544, **2007**
- Epstein FH, Agmon Y, Brezis M:** Physiology of renal hypoxia. *Ann NY Acad Sci* 718: 72–81, **1994**

- Erwig LP, Stewart K, Rees AJ:** Macrophages from inflamed but not normal glomeruli are unresponsive to anti-inflammatory cytokines. *Am J Pathol* 156: 295–301, **2000**
- Faggiotto A, Poli A, Catapano AL:** Antioxidants and coronary artery disease. *Curr Opin Lipidol* 9: 541–549, **1998**
- Farquharson CA, Butler R, Hill A, et al:** Allopurinol improves endothelial dysfunction in chronic heart failure. *Circulation* 106:221–226, **2002**
- Fazzini F, Peri G, Doni A, Dell’Antonio G, Dal Cin E, Bozzolo E, D’Auria F, Praderio L, Ciboddo G, Sabbadini MG, Manfredi AA, Mantovani A, Querini PR:** PTX3 in small-vessel vasculitides: An independent indicator of disease activity produced at sites of inflammation. *Arthritis Rheum* 44: 2841–2850, **2001**
- Feldt-Rasmussen B:** Microalbuminuria, endothelial dysfunction and cardiovascular risk. *Diabetes Metab* 26: 64–66, **2000**
- Ferrara N:** Role of vascular endothelial growth factor in the regulation of angiogenesis. *Kidney Int* 56: 794–814, **1999**
- Ferretti G, Bacchetti T, Masciangelo S et al.** Lipid peroxidation in hemodialysis patients: effect of vitamin C supplementation. *Clin Biochem* 41: 381–386, **2008**
- Fichtlscherer S, Rosenberger G, Walter DH, et al.** Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease. *Circulation*. 102:1000–1006, **2000**
- Fine LG, Orphanides C, Norman JT:** Progressive renal disease: the chronic hypoxia hypothesis. *Kidney Int* 65: S74–S78, **1998**
- Fish R, Nabel E, Selwyn A, et al:** Responses of coronary arteries of cardiac transplant patients to acetylcholine. *J Clin Invest* 81:21–31, **1988**
- Fliser D, Kronenberg F, Kielstein JT, Morath C, Bode-Boger SM, Haller H, Ritz E.** Asymmetric dimethylarginine and progression of chronic kidney disease: the mild to moderate kidney disease study. *J Am Soc Nephrol* 16: 2456–61, **2005**

- Floege J, Burns MW, Alpers CE, Yoshimura A, Pritzl P, Gordon K, Seifert RA, Bowen-Pope DF, Couser WG, Johnson RJ:** Glomerular cell proliferation and PDGF expression precede glomerulosclerosis in the remnant kidney model. *Kidney Int* 41: 297–309, **1992**
- Fogo A, Ichikawa I:** Evidence for a central role of glomerular growth promoters in the development of glomerulosclerosis. *Semin Nephrol* 9: 329–342, **1989**
- Folkman J:** Angiogenesis in cancer, vascular, rheumatoid and other disease. *Nat Med* 1: 27–31, **1995**
- Foley RN, Parfrey PS, Sarnak MJ:** Clinical epidemiology of cardiovascular disease in chronic renal disease. *Am J Kidney Dis* 32:S112–S119, **1998**
- Fortunõ A, Beloqui O, San José G et al.** increased phagocytic nicotinamideadenine dinucleotide phosphate oxidase-dependent superoxide production in patients with early chronic kidney disease. *Kidney Int Suppl* 99: S71–S75, **2005**
- Fouque D, Kalantar-Zadeh K, Kopple J, Cano N, Chauveau P, Cuppari L, Franch H, Guarnieri G, Ikizler TA, Kaysen G, Lindholm B, Massy Z, Mitch W, Pineda E, Stenvinkel P, Trevinho-Becerra A, Wanner C:** A proposed nomenclature and diagnostic criteria for protein-energy wasting in acute and chronic kidney disease. *Kidney Int* **2008**
- Fox CS, Larson MG, Vasan RS, Guo CY, Parise H, Levy D, Leip EP, O'Donnell CJ, D'Agostino RB, Benjamin EJ:** Crosssectional association of kidney function with valvular and annular calcification: The Framingham heart study. *J Am Soc Nephrol* 17: 521–527, **2006**
- Frank PG, Woodman SE, Park DS, Lisanti MP:** Caveolin, caveolae, and endothelial cell function. *Arterioscler Thromb Vasc Biol* 23: 1161–1168, **2003**
- Frazier W:** Thrombospondins. *Curr Opin Cell Biol* 3: 792–799, **1991**

- Freedman BI, Langefeld CD, Lohman KK, Bowden DW, Carr JJ, Rich SS, Wagenknecht LE:** Relationship between albuminuria and cardiovascular disease in type 2 diabetes. *J Am Soc Nephrol* 16: 2156–2161, **2005**
- Fried L, Solomon C, Shlipak M et al.** Inflammatory and prothrombotic markers and the progression of renal disease in elderly individuals. *J Am Soc Nephrol* 15: 3184–3191, **2004**
- Frisbee JC, Stepp DW:** Impaired NO-dependent dilation of skeletal muscle arterioles in hypertensive diabetic obese Zucker rats. *Am J Physiol Heart Circ Physiol* 281: H1304–H1311, **2001**
- Fukuhara A, Matsuda M, Nishizawa M et al.** Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. *Science* 307: 426–430, **2005**
- Galle J, Schneider R, Heinloth A, et al:** Lp (a) and LDL induce apoptosis in human endothelial cells and in rabbit aorta: Role of oxidative stress. *Kidney Int* 55:1450–1461, **1999**
- Ganz P, Vita JA:** Testing endothelial vasomotor function: Nitric oxide, a multipotent molecule. *Circulation* 108: 2049–2053, **2003**
- Gengrinovitch S, Berman B, David G, Witte L, Neufeld G, RonD:** Glypican-1 is a VEGF165 binding proteoglycan that acts as an extracellular chaperone for VEGF165. *J Biol Chem* 274:10816–10822, **1999**
- Gerber HP, Dixit V, Ferrara N:** Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells. *J Biol Chem* 273: 13313–13316, **1998**
- Gerber HP, McMurtrey A, Kowalski J, Yan M, Keyt BA, Dixit V, Ferrara N:** Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-Kinase/Akt signal transduction pathway. *J Biol Chem* 273: 30336–30343, **1998**
- Gerber H-P, Hillan K, Ryan A, Kowalski J, Keller G-A, Rangell L, Wright B, Radtke F, Aguet M, Ferrara N:** VEGF is required for growth and survival in neonatal mice. *Development* 126:1149–1159, **1999**

- Gilbert RE, McNally PG, Cox A, Dziadek M, Rumble J, Cooper ME, Jerums G:** SPARC gene expression is reduced in early diabetes related growth. *Kidney Int* 48: 1216–1225, **1995**
- Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY:** Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. *N Engl J Med* 351: 1296–1305, **2004**
- Goddard J, Eckhart C, Johnston NR, Cumming AD, Rankin AJ, Webb DJ:** Endothelin A receptor antagonism and angiotensin-converting enzyme inhibition are synergistic via an endothelin B receptor-mediated and nitric oxide-dependent mechanism. *J Am Soc Nephrol* 15: 2601–2610, **2004**
- Goddard J, Johnston NR, Hand MF, Cumming AD, Rabelink TJ, Rankin AJ, Webb DJ:** Endothelin-A receptor antagonism reduces blood pressure and increases renal blood flow in hypertensive patients with chronic renal failure: A comparison of selective and combined endothelin receptor blockade. *Circulation* 109: 1186–1193, **2004**
- Goddard J, Dhaun N and David J:** The endothelin system and its antagonism in chronic kidney disease, *J Am Soc Nephrol* 17:943–955, **2006**
- Goldin A, Beckman JA, Schmidt AM, Creager MA:** Advanced glycation end products: Sparking the development of diabetic vascular injury. *Circulation* 114: 597–605, **2006**
- Griendling KK, FitzGerald GA:** Oxidative stress and cardiovascular injury: Part I: Basic mechanisms and in vivo monitoring of ROS. *Circulation* 108: 1912–1916, **2003**
- Grone J-J, Simon M, Grone EF:** Expression of vascular endothelial growth factor in renal vascular disease and renal allografts. *J Pathol* 177: 259–267, **1995**
- Guo N, Krutzsch HC, Inman JK, Roberts DD:** Thrombospondin 1 and type 1 repeat peptides of thrombospondin 1 specifically induce apoptosis of endothelial cells. *Cancer Res* 57: 1735–1742, **1997**
- Gwinner W, Landmesser U, Brandes RP, et al:** Reactive oxygen species and antioxidant defense in puromycin aminonucleoside glomerulopathy. *J Am Soc Nephrol* 8:1722–1731, **1997**

- Haitoglou CS, Tsilibary EC, Brownlee M, Charonis AS:** Altered cellular interactions between endothelial cells and non enzymatically glycosylated laminin/type IV collagen. *J Biol Chem* 267: 12404–12407, **1992**
- Hallan SI, Dahl K, Oien CM, Grootendorst DC, Aasberg A, Holmen J, Dekker FW:** Screening strategies for chronic kidney disease in the general population: Follow-up of cross sectional health survey. *BMJ* 333: 1047, **2006**
- Hamilton CA, Brosnan MJ, Al-Benna S, Berg G, Dominiczak AF:** NAD(P)H oxidase inhibition improves endothelial function in rat and human blood vessels. *Hypertension* 40: 755–762, **2002**
- Hannken T, Schroeder R, Zahner G, et al:** Reactive oxygen species stimulate p44/42 mitogen-activated protein kinase and induce p27Kip1: Role in angiotensin II-mediated hypertrophy of proximal tubular cells. *J Am Soc Nephrol* 11:1387–1397, **2000**
- Harris RC:** Cyclooxygenase-2 in the kidney. *J Am Soc Nephrol* 11:2387–2394, **2000**
- Heeschen C, Aicher A, Lehmann R, Fichtlscherer S, Vasa M, Urbich C, Mildner-Rihm C, Martin H, Zeiher AM, Dimmeler S:** Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. *Blood* 102: 1340–1346, **2003**
- Heinloth A, Heermeier K, Raff U, et al:** Stimulation of NADPH oxidase by oxidized LDL induces proliferation of human vascular endothelial cells. *J Am Soc Nephrol* 11:1819–1825, **2000**
- Heitzer T, Schlinzig T, Krohn K, Meinertz T, Munzel T:** Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. *Circulation* 104: 2673–2678, **2001**
- Hermans MM, Brandenburg V, Ketteler M, Kooman JP, van der Sande FM, Boeschoten EW, Leunissen KM, Krediet RT, Dekker FW:** Association of serum fetuin-A levels with mortality in dialysis patients. *Kidney Int* 72: 202–207, **2007**
- Herrera M, Garvin JL.** Recent advances in the regulation of nitric oxide in the kidney. *Hypertension* 45: 1062–7, **2005**

- Herrero I, Torras J, Riera M, et al.** Prevention of cold ischemia reperfusion injury by an endothelin receptor antagonist in experimental renal transplantation. *J Am Soc Nephrol* 8: 657 A (abstr), **1997**
- Hewitson TD, Darby IA, Bisucci T, Jones CL, Becker GJ:** Evolution of tubulointerstitial fibrosis in experimental renal infection and scarring. *J Am Soc Nephrol* 9: 632–642, **1998**
- Higashi Y, Sasaki S, Nakagawa K, et al :** Endothelial function and oxidative stress in renovascular hypertension. *N Engl J Med* 346:1954–1962, **2002**
- Hill JM, Zalos G, Halcox JP, Schenke WH, Waclawiw MA, Quyyumi AA, Finkel T:** Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. *N Engl J Med* 348:593–600, **2003**
- Himmelfarb J, McMenamin E, Loseto G, Heinecke JW:** Myeloperoxidase-catalyzed 3-chlorotyrosine formation in dialysis patients. *Free Radic Biol & Med* 31: 1163–1169, **2001**
- Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM:** The elephant in uremia: Oxidant stress as a unifying concept of cardiovascular disease in uremia. *Kidney Int* 62: 1524–1538, **2002**
- Himmelfarb J, Kane J, McMonagle E, Zaltas E, Bobzin S, Boddupalli S, Phinney S, Miller G:** Alpha and gamma tocopherol metabolism in healthy subjects and patients with end-stage renal disease. *Kidney Int* 64: 978–991, **2003**
- Hodge DR, Xiao W, Clausen PA, Heidecker G, Szyf M, Farrar WL:** Interleukin-6 regulation of the human DNA methyltransferase (HDNMT) gene in human erythroleukemia cells. *J Biol Chem* 276: 39508–39511, **2001**
- Hofbauer LC, Brueck CC, Shanahan CM, Schoppet M, Dobnig H:** Vascular calcification and osteoporosis: From clinical observation towards molecular understanding. *OsteoporosInt* 18: 251–259, **2007**

- Honing MLH, Bouter PK, Ballard DE, Padley P, Morrison PJ, Rabelink, TJ:** ABT-627, a selective ETA-receptor antagonist, reduces proteinuria in patients with diabetes mellitus. In: Regulation of Vascular Tone in Humans by Endothelium-Derived Mediators [Doctoral thesis]. University of Utrecht, pp 89–102 , **2000**
- Horita Y, Miyazaki M, Koji T, Kobayashi N, Shibuya M, Razzaque MS, Cheng M, Ozono Y, Kohno S, Taguchi T:** Expression of vascular endothelial growth factor and its receptors in rats with protein overload nephrosis. *Nephrol Dial Transpl* 13:2519–2528, **1998**
- Hotamisligil GS:** Inflammation and metabolic disorders. *Nature* 444: 860–867, **2006**
- Hou FF, Ren H, Owen WF, Guo ZJ, Chen PY, Schmidt AM, Miyata T, Zhang X:** Enhanced expression of receptor for advanced glycation end products in chronic kidney disease. *J Am Soc Nephrol* 15: 1889–1896, **2007**
- Hughes J, Nangaku M, Alpers CE, Shankland SJ, Couser WG, Johnson RJ:** The C5b-9 membrane attack complex mediates endothelial cell apoptosis in experimental glomerulonephritis. *Am J Physiol* 278: F747–F757, **2000**
- Hugo C, Pichler R, Meek R, Gordon K, Kyriakides T, Floege J, Bornstein P, Couser Johnson RJ:** Thrombospondin I is expressed by proliferating mesangial cells in vivo and is regulated by PDGF and bFGF. *Kidney Int* 48: 1846–1856, **1995**
- Hugo C, Shankland S, Pichler R, Couser WG, Johnson RJ:** Thrombospondin 1, a TGF-beta activating protein, precedes and predicts the development of tubulointerstitial fibrosis in glomerular disease. *Kidney Int* 53: 302–311, **1998**
- Hyndman ME, Verma S, Rosenfeld RJ, Anderson TJ, Parsons HG:** Interaction of 5-methyltetrahydrofolate and tetrahydrobiopterin on endothelial function. *Am J Physiol Heart Circ Physiol* 282: H2167–H2172, **2002**

- Hyre AD, Fox CS, Astor BC, Cohen AJ, Muntner P:** The impact of reclassifying moderate CKD as a coronary heart disease risk equivalent on the number of US adults recommended lipid-lowering treatment. *Am J Kidney Dis* 49: 37–45, **2007**
- Ibsen H, Olsen MH, Wachtell K, Borch-Johnsen K, Lindholm LH, Mogensen CE, Dahlof B, Devereux RB, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Lederballe-Pedersen O, Nieminen MS, Omvik P, Oparil S, Wan Y:** Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: Losartan Intervention for Endpoint Reduction in Hypertension Study. *Hypertension* 45: 198–202, **2005**
- Iervasi G, Pingitore A, Landi P, Raciti M, Ripoli A, Scarlattini M, L'Abbate A, Donato L:** Low-T3 syndrome: A strong prognostic predictor of death in patients with heart disease. *Circulation* 107: 708–713, **2003**
- Iglarz M, Touyz RM, Amiri F, Lavoie MF, Diep QN, Schiffrin EL:** Effect of peroxisome proliferator-activated receptor- α and - γ activators on vascular remodeling in endothelin dependent hypertension. *Arterioscler Thromb Vasc Biol* 23: 45–51, **2003**
- Ignacy W, Chudek J, Adamczak M, Funahashi T, Matsuzawa Y, Kokot F, Wiecek A:** Reciprocal association of plasma adiponectin and serum C-reactive protein concentration in haemodialysis patients with end-stage kidney disease: A follow-up study. *Nephron Clin Pract* 101: c18–c24, **2005**
- Ingrosso D, Cimmino A, Perna AF, Masella L, de Santo NG, De Bonis ML, Vacca M, Desposito M, Durso M, Galletti P, Zappia V:** Folate treatment and unbalanced methylation and changes of allelic expression induced by hyperhomocysteinemia in patients with uremia. *Lancet* 361: 1693–1699, **2003**
- Iruela-Arispe L, Gordon KL, Hugo C, Duijvestijn A, Claffey K, Reilly M, Couser WG, Alpers CE, Johnson RJ:** Participation of the glomerular endothelial cell in capillary repair in glomerulonephritis. *Am J Pathol* 147: 1715–1727, **1995**

- Ishidoya S, Morrissey J, McCracken R, Klahr S:** Delayed treatment with enalapril halts tubulointerstitial fibrosis in rats with obstructive nephropathy. *Kidney Int* 49: 1110–1119, **1996**
- Ivanovski O, Szumila D, Nguyen-Khoa T, Ruellan N, Phan O, Lacour B, Descamps-Latscha, Druke TB, Massy Z:** The antioxidant N-acetylcysteine prevents accelerated atherosclerosis in uremic apolipoprotein E knockout mice. *KidneyInt* 67: 2288–2294, **2005**
- Iwasaki S, Homma T, Matsuda Y, Kon V.** Endothelin receptor subtype B mediates autoinduction of endothelin-1 in rat mesangial cells. *J Biol Chem* 270: 6997–7003, **1995**
- Ix JH, Shiplak MG, Sarnak MJ, Beck GJ, Greene T, Wang X, Kusek JW, Collins AJ, Levey AS, Menon V:** Fetuin-A is not associated with mortality in chronic kidney disease. *KidneyInt* 72: 1394–1399, **2007**
- Jabs WJ, Loering BA, Gerke P et al.** The kidney as a second site of human C-reactive protein formation in vivo. *Eur J Immunol* 33:152–161, **2003**
- Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, deJong PE, de Zeeuw D, Shahinfar S, Toto R, Levey AS:** Progression of chronic kidney disease: The role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: A patient-level meta-analysis. *Ann InternMed* 139: 244–252, **2003**
- Jamison RL, Hartigan P, Kaufman JS, Goldfarb DS, WarrenSR, Guarino PD, Gaziano JM:** Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease. *JAMA* 10: 1163–1170, **2007**
- Jan Galle, Thomas quaschnig, Stefan Seibol, and Christoph Wanner** Endothelial dysfunction and inflammation : What is the link ? Vol.63, Supplement 84 pp. S 45–S49, **2003**
- John S, Schlaich M, Langenfeld M, et al.** Increased bioavailability of nitric oxide after lipid-lowering therapy in hypercholesterolemic patients:a randomized, placebo-controlled, double-blind study. *Circulation.* 98:211–216, **1998**

- Johnson RJ, Kang DH, Feig D, et al:** Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? *Hypertension* 41:1183–1190, **2003**
- Kalantar-Zadeh K, Block G, Humphreys MH, Kopple JD:** Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. *Kidney Int* 63: 793–808, **2003**
- Kalantar Zadeh K, Abbott KC, Salahudeen AK, Kilpatrick RD, Horwich TB:** Survival advantages of obesity in dialysis patients. *Am J Clin Nutr* 81: 543–554, **2005**
- Kalantar-Zadeh K, Kilpatrick RD, Kuwae N, Wu DY:** Reverse epidemiology: A spurious hypothesis or a hardcore reality? *Blood Purif* 23: 57–63, **2005**
- Kalantar Zadeh K, Brennan ML, Hazen SL:** Serum myeloperoxidase and mortality in maintenance hemodialysis patients. *Am J Kidney Dis* 48: 59–68, **2006**
- Kanabrocki EL, ThirdJL, Ryan MD, et al:** Circadian relationship of serum uric acid and nitric oxide. *JAMA* 283:2240–2241, **2000**
- Kanellis J, Fraser S, Katerelos M, Power DA:** Vascular endothelial growth factor is a survival factor for renal tubular epithelial cells. *Am J Physiol Renal Physiol* 278: F905–F915, **2000**
- Kang DH, Anderson S, Kim YG, Mazzali M, Suga S, Jefferson JA, Gordon KL, Oyama TT, Hughes J, Hugo C, Kerjaschki D, Schreiner GF, Johnson RJ:** Impaired angiogenesis in the aging kidney: Potential role of VEGF and TSP-1 in renal disease. *Am J Kid Dis* 37: 601–611, **2001**
- Kang DH, Joly AH, Oh SW, Hugo C, Kerjaschki D, Gord KL, Mazzali M, Jefferson JA, Hughes J, Madsen KM, Schreiner GF, Johnson RJ:** Impaired angiogenesis in the remnant kidney model (I): Potential role of vascular endothelial growth factor and thrombospondin-1. *J Am Soc Nephrol* 12: 1434–1447, **2001**
- Kang DH, Nakagawa T, Feng L, Lan H, Johnson RJ:** Changes in renal micro- and macrovasculature induced by inhibition of nitric oxide synthesis in the remnant kidney model: New Mechanism for Progression of Renal Disease. *J Am Soc Nephrol* 12:816A–817A, **2001**

- Kaptein EM:** Thyroid hormone metabolism and thyroid diseases in chronic renal failure. *Endocr Rev* 17: 45–63, **1996**
- Karamouzis I, Sarafidis PA, Karamouzis M et al.** Increase in oxidative stress but not in antioxidant capacity with advancing stages of chronic kidney disease. *Am J Nephrol* 28: 397–404, **2008**
- Kawano H, Motoyama T, Hirai N, Kugiyama K, Yasue H, Ogawa H:** Endothelial dysfunction in hypercholesterolemia is improved by L-arginine administration: Possible role of oxidative stress. *Atherosclerosis* 161: 375–380, **2002**
- Kazama JJ, Shigematsu T, Yano K, Tsuda E, Miura M, Iwasaki Y, Kawaguchi Y, Gejyo F, Kurokawa K, Fukagawa M:** Increased circulating levels of osteoclastogenesis inhibitory factor (osteoprotegerin) in patients with chronic renal failure. *Am J Kidney Dis* 39: 525–532, **2002**
- Keller G, Zimmer G, Mall G, Ritz E, Amann K.** Nephron number in patients with primary hypertension. *N Engl J Med* 348: 101-8, **2003**
- Ketteler M, Bongartz P, Westenfeld R, Wildberger JE, Mahnken AH, Böhm R, Metzger T, Wanner C, Jahnke D, Floege J:** Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: A cross-sectional study. *Lancet* 361: 327–333, **2003**
- Kielstein JT, Boger RH, Bode-Boger SM, Frolich JC, Haller H, Ritz E, Fliser D:** Marked increase of asymmetric dimethylarginine in patients with incipient primary chronic renal disease. *J Am Soc Nephrol* 13: 170–176, **2002**
- Kielstein JT, Bode-Boger SM, Frolich JC, Ritz E, Haller H, Fliser D:** Asymmetric dimethylarginine, blood pressure, and renal perfusion in elderly subjects. *Circulation* 107: 1891–1895, **2003**
- Kielstein JT, Imrain B, Simmel S, Bode-Boger SM, Tsikas D, Frolich JC, Hoepfer MM, Haller H, Fliser D.** Cardiovascular effects of systemic nitric oxide synthase inhibition with asymmetrical dimethylarginine in humans. *Circulation* 109: 172-7, **2004**

- Kielstein JT, Zoccali C:** Asymmetric dimethylarginine: A cardiovascular risk factor and a uremic toxin coming of age. *Am J Kidney Dis* 46: 186–202, **2005**
- Kim Y-G, Suga S, Kang D-H, Jefferson JA, Mazzali M, Gordon KL, Matsui K, Breiteneder-Geleff S, Shankland SJ, Hughes J, Kerjaschki D, Schreiner GF, Johnson RJ:** Vascular endothelial growth factor accelerates renal recovery in experimental thrombotic microangiopathy. *Kidney Int* 58: 2390–2399, **2000**
- Kim YK, Lee MS, Son SM, Kim IJ, Lee WS, Rhim BY, Hong KW, Kim CD:** Vascular NADH oxidase is involved in impaired endothelium-dependent vasodilation in OLETF rats, a model of type 2 diabetes. *Diabetes* 51: 522–527, **2002**
- Kim SR, Bae SK, Choi KS et al.** Visfatin promotes angiogenesis by activation of extracellular signal-regulated kinase 1/2. *BiochemBiophys Res Commun* 357: 150–156, **2007**
- Kinlay S, Libby P, Ganz P.** Endothelial function and coronary artery disease. *Curr Opin Lipidol.* 12:383–389, **2001**
- Kistorp C, Faber J, Galatius S, Gustafsson F, Frystyk J, Flyvbjerg A, Hildebrandt P:** Plasma adiponectin, body mass index and mortality in patients with chronic heartfailure. *Circulation* 112: 1756–1762, **2005**
- Kitamoto Y, Tokunaga H, Tomita K:** Vascular endothelial growth factor is an essential molecule for mouse kidney development. *J Clin Invest* 99: 2351–2357, **1997**
- Kitamura H, Shimizu A, Masuda Y, Ishizaki M, Sugisaki Y, Yamanaka N:** Apoptosis in glomerular endothelial cells during the development of glomerulosclerosis in the remnant kidney model. *Exp Nephrol* 6: 328–336, **1998**
- Klahr, Schreiner G, Ichikawa I:** The progression of renal disease *N Engl J Med* 318: 1657–66, **1988**
- Klahr S:** Oxygen radicals and renal diseases. *Miner Electrolyte Metab* 23:140–143, **1997**

- Kon V, Hunley TE, Fogo A.** Combined antagonism of endothelinA/Breceptors links endothelin to vasoconstriction whereas angiotensin II affects fibrosis. *Transplantation* 60: 89–95, **1995**
- Kottgen A, Russel SD, Loehr LR, Crainiceanu CM, Rosamond WD, Chang PP, Chambless LE, Coresh J:** Reduced kidney function as a risk factor for incident heart failure:The Atherosclerosis Risk in Communities (ARIC) study.*J Am Soc Nephrol* 18: 1307–1315, **2007**
- Kovacs A, Tornvall P, Nilsson R, Tegner J, Hamsten A, Bjoörkegren J:** Human C-reactive protein slows atherosclerosis development in a mouse model with human-like hypercholesterolemia. *Proc Natl Acad Sci U S A* 104: 13768–13773, **2007**
- Kovesdy CP, Anderson JE:** Reverse epidemiology in patients with chronic kidney disease who are not yet on dialysis. *Semin Dial* 20: 566–569, **2007**
- Kriz W:** Progressive renal failure-inability of podocytes to replicate and the consequences for development of glomerulosclerosis.*Nephrol Dial Transpl* 11: 1738–1742, **1996**
- Kriz W, Gretz N, Lemley KV:** Progression of glomerular diseases: Is the podocyte the culprit? *Kidney Int* 54: 687–697, 1998697, **1998**
- Kupprion C, Matamed K, Sage EH:** SPARC (BM- 40, osteonectin) inhibits the mitogenic effect of vascular endothelial growth factor on microvascular endothelial cells. *J Biol Chem* 273:29635–29640, **1998**
- Labarrere CA, Zaloga GP.** C-reactive protein: from innocent bystander to pivotal mediator of atherosclerosis. *Am J Med* 117: 499–507, **2004**
- Lahera V, Goicoechea M, de Vinuesa SG et al.** Oxidative stress in uremia:the role of anemia correction. *J Am Soc Nephrol* 17(Suppl 3):S174–S177, **2006**
- Landmesser U, Spiekermann S, Dikalov S, Tatge H, Wilke R, Kohler C, Harrison DG, Hornig B, Drexler H:** Vascular oxidative stress and endothelial dysfunction in patients with chronic heart failure: Role of xanthine-oxidase and extracellular superoxide dismutase. *Circulation* 106: 3073–3078, **2002**

- Landmesser U, Dikalov S, Price SR, McCann L, Fukai T, Holland SM, Mitch WE, Harrison DG:** Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. *J Clin Invest* 111: 1201–1209, **2003**
- Lee LK, Meyer TW, Pollock AS, Lovett DH:** Endothelial cell injury initiates glomerular sclerosis in the rat remnant kidney. *J Clin Invest* 96: 953–964, **1995**
- Lee NK, Sowa H, Hinoi E, Ferron M, Ahn JD, Confavreux C, Dacquin R, Mee PJ, McKee MD, Jung DY, Zhang Z, Kim JK, Mauvais-Jarvis F, Ducy P, Karsenty G:** Endocrine regulation of energy metabolism by the skeleton. *Cell* 130:456–469, **2007**
- Lembo G, Vecchione C, Fratta L et al.** Leptin induces direct vasodilation through distinct endothelial mechanisms. *Diabetes* 49:293–297, **2000**
- Lerman A, Edwards BS, Hallett JW, Heublein DM, Sandberg SM, Burnett JC.** Circulating and tissue endothelin immune reactivity in advanced atherosclerosis. *N Engl J Med* 325: 997–1001, **1991**
- Li H, Lewis A, Brodsky S, et al :** Homocysteine induces HMGCoA reductase in vascular endothelial cells : A mechanism for development of atherosclerosis. *Circulation* 105:1037–1043, **2002**
- Li H, Brodsky S, Brink P, et al :** Paradoxical overexpression and translocation of connexin-43 in homocysteine-treated endothelial cells. *Am J Physiol Heart* 282:H2124–H2133, **2002**
- Li H, Goligorsky MS :** Endothelial gene responses to homocysteine: Relation to atherosclerosis. *Exp Nephrol* 10:164–169, **2002**
- Libby P.** Inflammation in atherosclerosis. *Nature* 420: 868–874, **2002**
- Lim SC, Caballero AE, Smakowski P, LoGerfo FW, Horton ES, Veves A:** Soluble intercellular adhesion molecule, vascular cell adhesion molecule, and impaired microvascular reactivity are early markers of vasculopathy in type 2 diabetic individuals without microalbuminuria. *Diabetes Care* 22: 1865–1870, **1999**

- Lin-Tan DT, Lin JL, Wang LH, Wang LM, Huang LM, Liu L, Huang JY, Huang Y:** Fasting glucose levels in predicting 1-year all-cause mortality in patients who do not have diabetes and are on maintenance hemodialysis. *J Am Soc Nephrol* 18: 2385–2391, **2007**
- Liu Y, Coresh J, Eustace JA, Longnecker JC, Jaar B, Fink NE, Tracy RP, Powe NR, Klag MJ:** Association between cholesterol level and mortality in dialysis patients. Role of inflammation and malnutrition. *JAMA* 291: 451–459, **2004**
- Liu Y, Berthier-Schaad Y, Fallin MD, Fink NE, Tracy RP, Klag MJ, Smith MW, Coresh J:** Interleukin 6 haplotypes, inflammation, and risk of cardiovascular disease in a multiethnic dialysis cohort. *J Am Soc Nephrol* 17: 863–870, **2006**
- Lo JC, Chertow GM, Go AS, Hsu CY:** Increased prevalence of subclinical and clinical hypothyroidism in persons with chronic kidney disease. *Kidney Int* 67: 1047–1052, **2005**
- Locatteli F, Pisoni F, Combe RL, Bommer J, Andreucci VE, Piera L, Greenwood R, Feldman HI, Port FK, Held PJ:** Anaemia in haemodialysis patients of five European countries: Association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). *Nephrol Dial Transpl* 19: 121–132, **2004**
- London GM, Pannier B, Agharazii M, Guerin AP, Verbeke FH, Marchais SJ:** Forearm reactive hyperemia and mortality in end-stage renal disease. *Kidney Int* 65: 700–704, **2004**
- London GM, Guerin AP, Verbeke FH, Pannier B, Boutouyrie P, Marchais SJ, Metivier F:** Mineral metabolism and arterial functions in end-stage renal disease: Potential role of 25-hydroxyvitamin D deficiency. *J Am Soc Nephrol* 18: 613–620, **2007**
- Lowrie EG, Lew NL:** Death risk in hemodialysis patients: The predictive value of commonly measured variables and an evaluation of death rate differences between facilities. *Am J Kidney Dis* 15: 458–482, **1990**
- Lu'scher TF, Barton M.** Biology of the endothelium. *Clin Cardiol.* 20(suppl II):II-3-II-10, **1997**

- Ludmer PL, Selwyn AP, Shook TL, et al.** Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. *N Engl J Med*. 315:1046–1051, **1986**
- Madero M, Sarnak MJ, Wang X, Castaneda Sceppe C, Greene T, Beck GJ, Kusek JW:** Body mass index and mortality in CKD. *Am J Kidney Dis* 50: 404–411, **2007**
- Mallamaci F, Zoccali C, Tripepi G, Fermo I, Benedetto FA, Cataliotti A, Bellanuova I, Malatino LS, Soldarini A:** Hyperhomocysteinemia predicts cardiovascular outcomes in hemodialysis patients. *Kidney Int* 61: 609–614, **2002**
- Malle E, Woenckhaus C, Waeg G, Esterbauer H, Grone EF, Grone HJ:** Immunological evidence for hypochlorite-modified proteins in human kidney. *Am J Pathol* 150: 603–615, **1997**
- Manowitz NR, Mayor GH, Klepper MJ, DeGroot LJ:** Subclinical hypothyroidism and euthyroid sick syndrome in patients with moderate-to-severe congestive heart failure. *Am J Ther* 3: 797–801, **1996**
- Mantovani A, Garlanda C, Bottazzi B, Peri G, Doni A, Martinez de la Torre Y, Latini R:** The long pentraxin PTX3 in vascular pathology. *Vascul Pharmacol* 45: 326–330, **2006**
- Mantovani A, Garlanda C, Doni A, Bottazzi B:** Pentraxins in innate immunity: From C-reactive protein to the long pentraxin PTX3. *J Clin Immunol* 28: 1–13, **2008**
- Marcussen N, Nyengaard J, Christensen S:** Compensatory growth of glomeruli is accomplished by an increased number of glomerular capillaries. *Lab Invest* 70: 868–874, **1994**
- Massy ZA, Borderie D, Nguyen-Khoa T, Drueke TB, Ekindjian OG, Lacour B:** Increased plasma S-nitrosothiol levels in chronic haemodialysis patients. *Nephrol Dial Transpl* 18: 153–157, **2003**
- Masuda Y, Shimizu A, Mori T, Ishiwata T, Kitamura H, Ohashi R, Ishizaki M, Asano G, Sugisaki Y, Yamanaka N:** Vascularendothelial growth factor enhances glomerular capillary repair and accelerates resolution of experimentally induced glomerulonephritis. *Am J Pathol* 159: 599–608, **2001**

- Mather KJ, Verma S, Anderson TJ.** Improved endothelial function with metformin in type 2 diabetes mellitus. *J Am Coll Cardiol.* 37:1344–1350, **2001**
- Matsumoto Y, Ueda S, Yamagishi S, Matsuguma K, Shibata R, Fukami K, Matsuoka H, Imaizumi T, Okuda S.** Dimethylarginine dimethylaminohydrolase prevents progression of renal dysfunction by inhibiting loss of peritubular capillaries and tubulointerstitial fibrosis in a rat model of chronic kidney disease. *J Am Soc Nephrol* 18: 1525-33, **2007**
- Mazzali M, Hughes J, KimYG, et al:** Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. *Hypertension* 38:1101–1106, **2001**
- Mehta JL, Li DY, Chen HJ, Joseph J, Romeo F:** Inhibition of LOX-1 by statins may relate to upregulation of eNOS. *Biochem Biophys Res Commun* 289: 857–861, **2001**
- Menon V, Li L, Wang X, Greene T, Balakrishnan V, MaderoM, Pereira AP, Beck GJ, Kusek JW, Collins AJ, Levey AS, Sarnak MJ:** Adiponectin and mortality in patients with chronic kidney disease. *J Am Soc Nephrol* 17: 2599–2606, **2006**
- Merino A, Nogueras S, Buendía P et al.** Microinflammation and endothelial damage in hemodialysis. *Contrib Nephrol* 161:83–88, **2008**
- Meuus F, Kourilsky O, Guerin AP, et al:** Pathophysiology of cardiovascular disease in chronic renal disease. *Am J Kidney Dis* 32:S112–119, **2000**
- Michel CC, Neal CR:** Openings through endothelial cells associated with increased microvascular permeability. *Microcirculation* 6:45–54, **1999**
- Miles A, Miles E:** Vascular reactions to histamine-liberator and leukotaxine in the skin of guinea pigs. *J Physiol* 118:228–257, **1952**
- Miyata T, Sugiyama S, Saito A, Kurokawa K:** Reactive carbonyl compounds related uremic toxicity (“carbonyl stress”). *Kidney Int Suppl* 78: S25–S31, **2001**
- Modlinger PS, Wilcox CS, Aslam S.** Nitric oxide, oxidative stress, and progression of chronic renal failure. *Semin Nephrol* 24: 354-65, **2004**

- Molteni A, Ward W, Tsao C, et al:** Monocrotaline-induced pulmonary endothelial dysfunction in rats. *Proc Soc Exp Biol Med* 176:88–94, **1984**
- Morawietz H, Rueckschloss U, Niemann B, Duerrschmidt N, Galle J, Hakim K, Zerkowski HR, Sawamura T, Holtz J:** Angiotensin II induces LOX-1, the human endothelial receptor for oxidized low-density lipoprotein. *Circulation* 100: 899–902, **1999**
- Moreland S, McMullen DM, Delaney CL, Lee VG, Hunt JT:** Venous smooth muscle contains vasoconstrictor ETB-like receptors. *Biochem Biophys Res Commun* 184: 100–06, **1992**
- Morena M, terrier N, Jaussent I, Leray-Moragues H, Chalabi L, Rivory JP, Maurice F, Delcourt C, Cristol JP, Canaud B, Dupuy AM:** Plasma osteoprotegerin is associated with mortality in hemodialysis patients. *J Am Soc Nephrol* 17:262–270, **2006**
- Muntner P, Hamm LL, Kusek JW, Chen J, Whelton PK, He J:** The prevalence of nontraditional risk factors for coronary heart disease in patients with chronic kidney disease. *Ann Intern Med* 140: 9–17, **2004**
- Muntner P, Astor BC, Folsom AR, Coresh J:** Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: Results from the Atherosclerosis Risk in Communities study. *J Am Soc Nephrol* 16:529–538, **2005**
- National Kidney Foundation.** NKF-K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification. *Am J Kidney Dis* 39: S46–64, **2002**
- Ng YY, Huang TP, Yang WC, Chen ZP, Yang AH, Mu W, Nikolic-Paterson DJ, Atkins RC, Lan HY:** Tubular epithelial myofibroblast transdifferentiation in progressive tubulointerstitial fibrosis in 5/6 nephrectomized rats. *Kidney Int* 54: 864–876, **1998**
- Nguyen-Khoa T, Massy ZA, De Bandt JP, Kebede M, Salama L, Lambrey G, Witko-Sarsat V, Drueke TB, Lacour B, Thevenin M:** Oxidative stress and haemodialysis: Role of inflammation and duration of dialysis treatment. *Nephrol Dial Transpl* 16: 335–340, **2001**
- Nickenig G, Sachinidis A, Michaelsen F, et al :** Upregulation of vascular angiotensin II receptor gene expression by low density lipoprotein in vascular smooth muscle cells. *Circulation* 95:473–478, **1997**

- Nicolic-Paterson D, Lan H, Atkins R:** Macrophages in renal injury. *Kidney Int* 45: 79–82, 1994
- Nijveldt RJ, Teerlink T, van Der Hoven B, Siroen MP, Kuik DJ, Rauwerda JA, Van Leeuwen PA:** Asymmetrical dimethylarginine (ADMA) in critically ill patients: High plasma ADMA concentration is an independent risk factor of ICU mortality. *Clin Nutr* 22: 23–30, 2003
- Nitta K, Ishizuka T, Horita S, Hayashi T, Ajiro A, Uchida K, Nihei H:** Soluble osteopontin and vascular calcification in hemodialysis patients. *Nephron* 89: 455–458, 2001
- Nitta K, Akaiba T, Uchida K, Kawashima A, Yumura W, Kabaya T, Nihei H:** The progression of vascular calcification and serum osteoprotegerin levels in patients on longterm hemodialysis. *Am J Kidney Dis* 42: 303–309, 2003
- Noiri E, Satoh H, Taguchi J, Brodsky SV, Nakao A, Ogawa Y,** :Association of eNOS Glu298Asp polymorphism with end-stage renal disease. *Hypertension* 40: 535-40, 2002
- Norman JT, Clark IM, Garcia PL:** Hypoxia promotes fibrogenesis in human renal fibroblasts. *Kdney Int* 58: 2351–2366, 2000
- Oberg BP, McMenamin E, Lucas FL, McMonagle E, Morrow J, Ikizler TA, Himmelfarb J:** Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. *Kidney Int* 65: 1009–1016, 2004
- Ohashi R, Kitamura H, Yamanaka N:** Peritubular capillary injury during the progression of experimental glomerulonephritis in rats. *J Am Soc Nephrol* 11: 47–56, 2000
- Okada T, Nakao T, Matsumoto H, Shino T, Nagaoka Y, Tomaru R, Wada T:** Association between markers of glycemic control, cardiovascular complications and survival in type 2 diabetic patients with end-stage renal disease. *J Int Med* 46: 807–814, 2007
- Olivetti G, Anversa P, Rigamonti W, Vitali-Mazza L, Loud A:** Morphometry of the renal corpuscle during normal postnatal growth and compensatory hypertrophy; a light microscope study. *Cell Biol* 75: 573–585, 1977

- Ong AC, Jowett TP, Firth JD, Burton S, Kitamura M, Fine LG:** Human tubular-derived endothelin in the paracrine regulation of renal interstitial fibroblast function. *ExpNephrol* 2: 134, **1994**
- Opie LH:** Cellular basis for therapeutic choices in heart failure. *Circulation* 110: 2559–2561, **2004**
- Osanai T, Saitoh M, Sasaki S, Tomita H, Matsunaga T, Okumura K:** Effect of shear stress on asymmetric dimethylarginine release from vascular endothelial cells. *Hypertension* 42: 985–990, **2003**
- Ostendorf T, Kunter U, Loos A, Eitner F, Regele H, Kerjaschki D, Janji N, Floege J:** Vascular endothelial growth factor(VEGF165) mediates glomerular endothelial repair. *J Clin Invest* 104: 913–923, **1999**
- Ouchi N, Kihara S, Arita Y et al.** Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. *Circulation* 100: 2473–2476, **1999**
- Pacher R, Stanek B, Hulsmann M, Koller-Strametz J, Berger R, Schuller M, Hartter E, Ogris E, Frey B, Heinz G, Maurer G:** Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure. *J Am Coll Cardiol* 27: 633–641, **1996**
- Paniagua R, Amato D, Vonesh E, Correa-Rotter R, Ramos A, Moran J, Mujais S:** Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized, controlled trial. *J Am Soc Nephrol* 13: 1307–1320, **2002**
- Park JB, Charbonneau F, Schiffrin EL:** Correlation of endothelial function in large and small arteries in human essential hypertension. *J Hypertens* 19: 415–420, **2001**
- Passauer J, Bussemaker E, Lassig G, Gross P:** Kidney transplantation improves endothelium-dependent vasodilation in patients with endstage renal disease. *Transplantation* 75: 1907–1910, **2003**
- Pecoits-Filho R, Barany B, Lindholm B, Heimbürger O, Stenvinkel P:** Interleukin-6 and its receptor is an independent predictor of mortality in patients starting dialysis treatment. *Nephrol Dial Transpl* 17: 1684–1688, **2002**

- Pedrinelli R, Giampietro O, Carmassi F, Melillo E, Dell’Omo G, Catapano G, Matteucci E, Talarico L, Morale M, De Negri F, et al:** Microalbuminuria and endothelial dysfunction in essential hypertension. *Lancet* 344: 14–18, **1994**
- Perticone F, Maio R, Tripepi G, Zoccali C.** Endothelial dysfunction and mild renal insufficiency in essential hypertension. *Circulation* 110: 821–5, **2004**
- Pichler R, Giachelli C, Young B, Alpers CE, Couser WG, Johnson RJ:** The pathogenesis of tubulointerstitial disease associated with glomerulonephritis: The glomerular cytokine theory. *Miner Electrolyte Metab* 26: 317–327, **1995**
- Pichler R, Bassuk JA, Hugo C, Reed MJ, Eng E, Gordon KL, Pippin J, Alpers CE, Couser WG, Sage EH, Johnson RJ:** SPARC is expressed by mesangial cells in experimental mesangial proliferative nephritis and inhibits PDGF-mediated mesangial cell proliferation in vitro. *Am J Pathol* 148: 1153–1169, **1996**
- Pichler R, Hugo C, Shankland S, Reed M, Bassuk J, Andoh T, Lombardi D, Schwartz S, Bennett W, Alpers C, Sage E, Johnson RJ, Couser WG:** SPARC is expressed in renal interstitial fibrosis and in renal vascular injury. *Kidney Int* 50: 1978–1989, **1996**
- Piecznik SR, Neustadt J.** Mitochondrial dysfunction and molecular pathways of disease. *Exp Mol Pathol* 83: 84–92, **2007**
- Pillebout E, Burtin M, Yuan HT, Briand P, Woolf AS, Friedlander G, Terzi F:** Proliferation and remodeling of the peritubular microcirculation after nephron reduction. Association with the progression of renal lesions. *Am J Pathol* 159: 547–560, **2001**
- Pingitore A, Landi P, Taddei MC, Ripoli A, L’Abbate A, Iervasi G:** Triiodothyronine levels for risk stratification of patients with chronic heart failure. *Am J Med* 118: 132–136, **2005**
- Pistrosch F, Herbrig K, Kindel B, Passauer J, Fischer S, Gross P.** Rosiglitazone improves glomerular hyperfiltration, renal endothelial dysfunction, and microalbuminuria of incipient diabetic nephropathy in patients. *Diabetes* 54: 2206–11, **2005**

- Pollock DM, Opgenorth TJ.** Evidence for endothelin-induced renal vasoconstriction independent of ETA receptor activation. *Am J Physiol* 264: R222–26, **1993**
- Popov D, Costache G, Georgescu A, Enache M:** Beneficial effects of L-arginine supplementation in experimental hyperlipemia-hyperglycemia in the hamster. *Cell Tissue Res* 308: 109–120, **2002**
- Portaluppi F, Boari B, Manfredini R.** Oxidative stress in essential hypertension. *Curr Pharm Des* 10: 1695–1698, **2004**
- Post WS, Goldschmidt-Clermont PJ, Wilhide CC, Heldman AW, Sussman MS, Ouyang P, Milliken EE, Issa JP:** Methylation of the estrogen receptor gene is associated with aging and atherosclerosis in the cardiovascular system. *Cardiovasc Res* 43: 985–991, **1999**
- Pupim LB, Himmelfarb J, McMonagle E, Shyr Y, Ikizler TA:** Influence of initiation of maintenance hemodialysis on biomarkers of inflammation and oxidative stress. *Kidney Int* 65: 2371–2379, **2004**
- Qi Y, Takahashi N, Hileman SM, Patel HR, Berg AH, Pajvani UB, Scherer PE, Ahima RS:** Adiponectin acts in the brain to decrease body weight. *Nature Med* 10: 524–529, **2004**
- Quiroz Y, Ferrebuz A, Romero F et al.** Melatonin ameliorates oxidative stress, inflammation, proteinuria, and progression of renal damage in rats with renal mass reduction. *Am J Physiol Renal Physiol* 294:F336–F444, **2008**
- Quyiumi AA, Dakak N, Andrews N, et al:** Nitric oxide activity in the human coronary circulation. Impact of risk factors for coronary atherosclerosis. *J Clin Invest* 95:1747–1753, **1995**
- Raggi P:** Coronary calcium on electron beam tomography imaging as a surrogate marker of coronary artery disease. *Am J Cardiol* 87: 27A–34A, **2001**
- Raggi P, Bellasi A, Ferramosca E, Block GA, Muntner P:** Pulse wave velocity is inversely related to vertebral bone density in hemodialysis patients. *Hypertension* 49: 1278–1284, **2007**

- Raggi P, Bellasi A, Ferramosca E, Islam T, Muntner P, Block GA:** Association of pulse wave velocity with vascular and valvular calcification in hemodialysis patients. *KidneyInt* 71: 802–807, **2007**
- Rambod M, Kovesdy CP, Kalantar-Zadeh K.** Malnutrition-inflammation score for risk stratification of patients with CKD: is it the promised goldstandard? *Nat Clin Pract Nephrol* 4: 354–355, **2008**
- Rao M, Wong C, Kanetsky P, Girndt M, Stenvinkel P, Reilly M, Raj DS:** Cytokine gene polymorphism and progression of renal and cardiovascular diseases. *Kidney Int* 72: 549–556, **2007**
- Ravani P, Tripepi G, Malberi F et al.** Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: a competing risk modeling approach. *J Am Soc Nephrol* 16:2449–2455, **2005**
- Reddan DN, Klassen PS, Szczech LA, Coladonato JA, O'Shea S, Owen WF, Lowrie EG:** White blood cells as a novel predictor in haemodialysis patients. *Nephrol DialTranspl* 18: 1167–1173, **2003**
- Reddy KG, Nair R, Sheehan H, Hodgson J:** Evidence that selective endothelial dysfunction may occur in the absence of angiographic or ultrasound atherosclerosis in patients with risk factors for atherosclerosis. *J Am Coll Cardiol* 23:833–843, **1994**
- Remuzzi G, Benigni A.** Endothelins in the control of cardiovascular and renal function. *Lancet* 342: 589–93, **1993**
- Remuzzi G, Ruggenenti P, Benigni A:** Understanding the nature of renal disease progression. *Kidney Int* 51: 2–15, **1997**
- Remuzzi G, Bertani T:** Pathophysiology of progressive nephropathies. *N Engl J Med* 339: 1448–1456, **1998**
- Richards EJ:** Inherited epigenetic variation: Revisiting soft inheritance. *Nature Reviews* 7: 395–400, **2006**
- Ridker PM.** Clinical application of C-reactive protein for cardiovascular disease detection and prevention. *Circulation*. 107:363–369, **2003**

- Roberts MA, Hare DL, Ratnaike S, Ierino FL:** Cardiovascular biomarkers in CKD: Pathophysiology and implications for clinical management of cardiac disease. *Am J Kidney Dis* 48: 341–360, **2006**
- Rosolowska-Huszcz D, Kozłowska L, Rydzewski A:** Influence of low protein diet on nonthyroidal illness syndrome in chronic renal failure. *Endocrine* 27: 283–288, **2005**
- Rossig L, Dimmeler S, Zeiher AM:** Apoptosis in the vascular wall and atherosclerosis. *Basic Res Cardiol* 96:11–22, **2001**
- Rubbo H, Trostchansky A, Botti H, et al.** Interactions of nitric oxide and peroxynitrite with low-density lipoprotein. *Biol Chem*. 383:547–552, **2002**
- Ruggenenti P, Perna A, Remuzzi G:** Retarding progression of chronic renal disease: The neglected issue of residual proteinuria. *Kidney Int* 63: 2254–2261, **2003**
- Sakata N, Imanaga Y, Meng J, Tachikawa Y, Takebayashi S, Nagai R, Horiuchi S:** Increased advanced glycation endproducts in atherosclerotic lesions of patients with end stage renal disease. *Atherosclerosis* 142: 67–77, **1999**
- Sakurai T, Yanagisawa M, Takuwa Y, Miyazaki H, Kimura S, Goto K, Masaki T:** Cloning of a cDNA encoding a non-isopeptide selective subtype of the endothelin receptor. *Nature* 348: 732–735, **1990**
- Sarnak MJ, Levey AS, Schoolwerth AC et al.** Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. *Hypertension* 42: 1050–1065, **2003**
- Savage T, Clarke AL, Giles M, Tomson CRV, Raine AEG:** Calcified plaque is common in the carotid and femoral arteries of dialysis patients without clinical vascular disease. *Nephrol Dial Transpl* 13: 2004–2012, **1998**
- Savill J, Hogg N, Ren Y, Haslett C:** Thrombospondin cooperates with CD36 and the vitronectin receptor in macrophage recognition of neutrophils undergoing apoptosis. *J Clin Invest* 90: 1513–1522, **1992**

- Savill J, Mooney A, Hughes J:** Apoptosis and renal scarring. *Kidney Int Suppl* 54: S14–17, **1996**
- Savvidou MD, Hingorani AD, Tsikas D, Frolich JC, Vallance P, Nicolaidis KH.** Endothelial dysfunction and raised plasma concentrations of asymmetric dimethylarginine in pregnant women who subsequently develop pre-eclampsia. *Lancet* 361: 1511–7, **2003**
- Scha"chinger V, Britten MB, Elsner M, et al.** A positive family history of premature coronary artery disease is associated with impaired endothelium- dependent coronary blood flow regulation. *Circulation*. 100:1502–1508, **1999**
- Schafer C, Heiss A, Schwarz A, Westenfeld R, Ketteler M, Floege J, Muller-Esterl W, Schinke T, Jahnke-Dechent W:** The serum protein alpha 2-Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. *J Clin Invest* 112: 357–366, **2003**
- Schiffrin EL, Thibault G:** Plasma endothelin in human essential hypertension. *Am J Hypertens* 4: 303–308, **1991**
- Schiffrin EL, Turgeon A, Deng LY.** Effect of chronic ETA-selective endothelin receptor antagonism on blood pressure in experimental and genetic hypertension in rats. *Br J Pharmacol* 121: 935–40, **1997**
- Schiffrin EL, Intengan HD, Thibault G, Touyz RM:** Clinical significance of endothelin in cardiovascular disease. *Curr OpinCardiol* 12: 354–367, **1997**
- Schiffrin EL, Park JB, Intengan HD, Touyz RM:** Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan. *Circulation* 101: 1653–1659, **2000**
- Schiffrin EL, Park JB, Pu Q:** Effect of crossing over hypertensive patients from a beta-blocker to an angiotensin receptor antagonist on resistance artery structure and on endothelial function. *J Hypertens* 20: 71–78, **2002**
- Schiffrin EL, Touyz RM:** Multiple actions of angiotensin II in hypertension: Benefits of AT1 receptor blockade. *J Am CollCardiol* 42: 911–913, **2003**

- Schillinger M, Mlekusch W, Haumer M, et al.** Relation of small artery compliance and lipoprotein(a) in patients with atherosclerosis. *Am J Hypertens*. 15:980–985, **2002**
- Schindler TH, Nitzsche EU, Munzel T, Olschewski M, Brink I, Jeserich M, Mix M, Buser PT, Pfisterer M, Solzbach U, Just H:** Coronary vasoregulation in patients with various risk factors inresponse to cold pressor testing: Contrasting myocardial blood flow responses to short- and long-term vitamin C administration.*J Am Coll Cardiol* 42: 814–822, **2003**
- Schlaich MP, John S, Langenfeld MRW, et al.** Does lipoprotein (a) impair endothelial function? *J Am Coll Cardiol*. 31:359–365, **1998**
- Schneider JG, Tilly N, Hierl T, Sommer U, Hamann A, Dugi K, Leidig-Bruckner G, Kasperk C:** Elevated plasma endothelin-1 levels in diabetes mellitus. *Am J Hypertens* 15: 967–972, **2002**
- Scholze A, Rattensperger D, Zidek W, Tepel M:** Low serum leptin predicts mortality in patients with chronic kidney disease stage 5. *Obesity* 15: 1617–1622, **2007**
- Schultz-Cherry S, Ribeiro S, Gentry L, Murphy-Ullrich JE:** Thrombospondin binds and activates the small and large forms of latent transforming growth factor-beta in a chemically defined system. *J Biol Chem* 269: 26775–26782, **1994**
- Schwarz U, Buzello M, Ritz E, Stein G, Raabe G, Wiest G, Mall G, Amann K:** Morphology of coronary atherosclerotic lesions in patients with end-stage renal failure. *Nephrol DialTransplant* 15: 218–223, **2000**
- Schwedler SB, Metzger T, Schinzel R, Wanner C:** Advanced glycation end products and mortality in hemodialysis patients.*Kidney Int* 62: 301–310, **2002**
- Sela S, Shurtz-Swiriski R, Cohen-Mazor M, Mazor R, Chezaz J, Shapiro G, Hassan K, Sckolnik G, Geron R, Kristal B:** Primed peripheral polymorponuclearleucyte: A culprit underlying chronic low-grade inflammation and systemic oxidative stress in chronic kidney disease. *J AmSoc Nephrol* 16: 2431–2438, **2005**

- Shankland SJ, Wolf G:** Cell cycle regulatory proteins in renal disease: Role in hypertrophy, proliferation, and apoptosis. *Am J Physiol Renal Physiol* 278: F515–F529, **2000**
- Shimabukuro M, Higa N, Asahi T et al.** Hypoadiponectinemia is closely linked to endothelial dysfunction in man. *J Clin Endocrinol Metab* 88: 3236–3240, **2003**
- Shimizu T, Hata S, Kuroda T, Mihara S, Fujimoto M:** Different roles of two types of endothelin receptors in partial ablation-induced chronic renal failure in rats. *Eur J Pharmacol* 381: 39–49, **1999**
- Shinohara K, Shoji T, Emoto M, Takahara H, Koyama H, Ishimura E, Miki T, Tabata T, Nishizawa Y:** Insulin resistance as an independent predictor of cardiovascular mortality in patients with end-stage renal disease. *J Am Soc Nephrol* 13: 1894–1900, **2002**
- Shlipak MG, Fried LF, Cushman M, Manolio TA, Peterson D, Stehman-Breen C, Bleyer A, Newman A, Siscovick D, Psaty B:** Cardiovascular mortality risk in chronic kidney disease: Comparison of traditional and novel risk factors. *JAMA* 293: 1737–1745, **2005**
- Shulman K, Rosen S, Tognazzi K, Manseau EJ, Brown LF:** Expression of vascular permeability factor (VPF/VEGF) is altered in many glomerular diseases. *J Am Soc Nephrol* 7: 661–666, **1996**
- Sigrist M, Bungay P, Taal MW, McIntyre CW:** Vascular calcification and cardiovascular function in chronic kidney disease. *Nephrol Dial Transplant* 21: 707–714, **2006**
- Simon M, Grone H-J, Johren O, Kullmer J, Plate KH, Risau W, Fuchs E:** Expression of vascular endothelial growth factor and its receptors in human renal ontogenesis and in adult kidney. *Am J Physiol* 268: F240–F250, **1995**
- Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D:** Correction of anemia with epoetin alfa in chronic kidney disease. *N Engl J Med* 355: 2085–2098, **2006**
- Smirnov A I, Kajstura M, Sawamura T, Goligorsky MS.** ADMA upregulates LOX-1 in activated macrophages: The role in foam cell formation. *Am J Physiol Heart* (in press)

- Smirnov A I, Sawamura T, Goligorsky MS:** Upregulation of LOX-1 in endothelial cells by nitric oxide deficiency. *Am J Physiol Renal* (in press)
- Sohn H-Y, Raff U, Hoffmann A, et al:** Differential role of Angiolipoprotein (a): Role of oxygen-derived radicals. *Circulation* 92: tensin II receptor subtypes on endothelial O₂ 1582–1589, 19952 formation. *Br J Pharmacol* 131:667–672, **2000**
- Soker S, Gollamudi-Payne S, Fidler H, Charnahelli H, Klagsbrun M:** Inhibition of vascular endothelial growth factor (VEGF)-induced endothelial cell proliferation by a peptide corresponding to the exon 7-encoded domain of VEGF165. *J Biol Chem* 272: 31582–31588, **1997**
- Sowers JR.** Hypertension, angiotensin II, and oxidative stress. *N Engl J Med*. 346:1999–2001, **2002**
- Spiegel DM, Raggi P, Smits G, Block GA:** Factors associated with mortality in patients new to haemodialysis. *Nephrol Dial Transpl* 22: 3568–3572, **2007**
- Stehouwer CD, Nauta JJ, Zeldenrust GC, Hackeng WH, Donker AJ, den Ottolander GJ:** Urinary albumin excretion, cardiovascular disease, and endothelial dysfunction in non-insulin-dependent diabetes mellitus. *Lancet* 340: 319–323, **1992**
- Steinberg D, Witztum JL.** Is the oxidative modification hypothesis relevant to human atherosclerosis? *Circulation*. 105:2107–2111, **2002**
- Stenvinkel P, Heimburger O, Paulter F, Diczfalusy U, Wang T, Berglund L, Jogestrand T:** Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. *Kidney Int* 55: 1899–1911, **1999**
- Stenvinkel P, Heimburger O, Wang T, Lindholm B, Bergstrom J, Elinder CG:** High serum hyaluronan indicates poor survival in renal replacement therapy. *Am J Kidney Dis* 34: 1083–1088, **1999**
- Stenvinkel P.** New insights on inflammation in chronic kidney disease genetic and non-genetic factors. *Nephrol Ther* 2: 111–119, **2006**

- Stenvinkel P, Karimi M, Johansson S, Axelsson J, Suliman M, Lindholm B, Heimbürger O, Barany P, Alvestrand A, Nordfors L, Qureshi AR, Ekström TJ, Schalling M:** Impact of inflammation on epigenetic DNA methylation: A novel risk factor for cardiovascular disease? *J Int Med* 261: 488–499, **2007**
- Stenvinkel P, Lindholm B:** Resolved: Being fat is good for dialysis patients: The Godzilla effect (Con). *J Am Soc Nephrol* **2008**
- Stenvinkel, JuanJesús Carrero, Jonas Axelsson, Bengt Lindholm, Olof Heimbürger, and Ziad Massy** Emerging Biomarkers for Evaluating Cardiovascular Risk in the Chronic Kidney Disease Patient: How Do New Pieces Fit into the Uremic Puzzle? The American Society of Nephrology, **2008**
- Stevens T, Rosenberg R, AIRD W, et al:** NHBLI workshop report: Endothelial cell phenotypes in heart, lung and blood diseases. *Am J Physiol Cell Physiol* 281:C1422-C1433, **2001**
- Stevens LA, Djurdjev O, Cardew S, Cameron EC, Levin A:** Calcium, phosphate, and parathyroid hormone levels in combination and as a function of dialysis duration predict mortality: Evidence for the complexity of the association between mineral metabolism and outcomes. *J Am Soc Nephrol* 15: 770–779, **2004**
- Stewart DJ, Levy RD, Cernacek P, Langleben D:** Increased plasma endothelin-1 in pulmonary hypertension: Marker or mediator of disease? *Ann Intern Med* 114: 464–469, **1991**
- Stuhlinger MC, Tsao PS, Her JH, Kimoto M, Balint RF, Cooke JP:** Homocysteine impairs the nitric oxide synthase pathway: Role of asymmetric dimethylarginine. *Circulation* 104: 2569–2575, **2001**
- Stuhlinger MC, Oka RK, Graf EE, Schmolzer I, Upson BM, Kapoor O, Szuba A, Malinow MR, Wascher TC, Pachinger O, Cooke JP:** Endothelial dysfunction induced by hyperhomocyst(e)inemia: Role of asymmetric dimethylarginine. *Circulation* 108: 933–938, **2003**

- Stuveling EM, Hillege HL, Bakker SJ, Asselbergs FW, deJong PE, Gans RO, de Zeeuw D.** C-reactive protein and microalbuminuria differ in their associations with various domains of vascular disease. *Atherosclerosis* 172:107-14, **2004**
- Suga SI, Phillips MI, Ray PE, Raleigh JA, Vio CP, Kim YG, Mazzali M, Gordon KL, Hughes J, Johnson RJ:** Hypokalemia induces renal injury and alterations in vasoactive mediators that favor salt sensitivity. *Am J Physiol Renal Physiol* 281: F620–F629, **2001**
- Sugiyama H, Kashihara N, Makino H, Yamasaki Y, Ota A:** Apoptosis in glomerular sclerosis. *Kidney Int* 49: 103–111, **1996**
- Suki WN, Zabaneh R, Cangiano JL, Reed J, Fisher D, Garrett L, Ling BN, Chasan-Taber S, Dillon MA, Blair AT, Burke SK:** Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. *KidneyInt* 72: 1130–1137, **2007**
- Suliman M, Heimbürger O, Barany P, Anderstam B, Pecoits-Filho R, Ayala ER, Fehrman I, Lindholm B, Stenvinkel P:** Plasma pentosidine is associated with inflammation and malnutrition in end-stage renal disease patients starting on dialysis therapy. *J Am Soc Nephrol* 14: 1614–1622, **2003**
- Suliman ME, Barany P, Kalantar-Zadeh K, Lindholm B, Stenvinkel P:** Homocysteine in uraemia: A puzzling and conflicting story. *Nephrol Dial Transpl* 20: 16–21, **2005**
- Suliman M, Stenvinkel P, Qureshi AR, Kalantar-Zadeh K, Barany P, Heimbürger O, Vonesh EF, Lindholm B:** The reverse epidemiology of plasma total homocysteine as a mortality risk factor is related to the impact of wasting and inflammation. *Nephrol Dial Transpl* 22: 209–217, **2007**
- Sunderkotter C, Steinbrink K, Goebeler M, Bhardwaj R, Sorg C:** Macrophages and angiogenesis *J Leukoc Biol* 55: 410–422, **1994**
- Suzuki T, Fukuo K, Suhara T, Yasuda O, Sato N, Takemura Y, Tsubakimoto M, Ogihara T:** Eicosapentaenoic acid protects endothelial cells against anoikis through restoration of cFLIP. *Hypertension* 42: 342–348, **2003**

- Szabo C, Mabley JG, Moeller SM, Shimanovich R, Pacher P, Virag L, Soriano FG, Van Duzer JH, Williams W, Salzman AL, Groves JT:** Part I: Pathogenetic role of peroxynitrite in the development of diabetes and diabetic vascular complications: Studies with FP15, a novel potent peroxynitrite decomposition catalyst. *Mol Med* 8: 571–580, **2002**
- Szmitko PE, Fedak PW, Weisel RD, Stewart DJ, Kutryk MJ, Verma S:** Endothelial progenitor cells: new hope for a broken heart. *Circulation* 107: 3093–3100, **2003**
- Taddei S, Virdis A, Mattei P, Ghiadoni L, Sudano I, Arrighi P Salvetti A:** Lack of correlation between microalbuminuria and endothelial function in essential hypertensive patients. *J Hypertens* 13: 1003–1008, **1995**
- Takebayashi K, Suetsugu M, Wakabayashi S et al.** Association between plasma visfatin and vascular endothelial function in patients with type 2 diabetes mellitus. *Metabolism* 56: 451–458, **2007**
- Taniyama Y, Griendling KK:** Reactive oxygen species in the vasculature. *Hypertension* 42: 1075–1081, **2003**
- Teitell M, Richardson B:** DNA methylation in the immune system. *Clin Immunol* 109: 2–5, **2003**
- Tepel M, van der Giet M, Statz M, Jankowski J, Zidek W:** The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure. *Circulation* 107: 992–995, **2003**
- Terawaki K, Yoshimura K, Hasegawa T et al.** Oxidative stress is enhanced in correlation with renal dysfunction: examination with the redox state of albumin. *Kidney Int* 66: 1989–1993, **2004**
- Thomas S, Vanuystel J, Gruden G, Rodriguez V, Burt D, Gnudi L, Hartley B, Viberti G:** Vascular endothelial growth factor receptors in human mesangium in vitro and in glomerular disease. *J Am Soc Nephrol* 11: 1236–1243, **2000**

- Timpson NJ, Lawlor DA, Harbord RM, Gaunt TR, Day IN, Palmer LJ, Hattersley AT, Ebrahim S, Lowe GD, Rumley A, Davey Smith G:** C-reactive protein and its role in metabolic syndrome: Mendelian randomization study. *Lancet* 366:1954–1959, **2005**
- Tonelli M, Pfeffer MA:** Kidney disease and cardiovascular risk. *Annu Rev Med* 58: 123–139, **2007**
- Tong M, Carrero JJ, Qureshi AR, Anderstam B, Heimbürger O, Barany P, Axelsson J, Alvestrand A, Stenvinke LP, Lindholm B, Suliman ME:** Plasma pentraxin 3 in patients with chronic kidney disease: associations with renal function, protein-energy wasting, cardiovascular disease, and mortality. *Clin J Am Soc Nephrol* 2: 889–897, **2007**
- Torpy DJ, Tsigos C, Lotsikas AJ, Defensor R, Chrousos GP, Papanicolaou DA:** Acute and delayed effects of a single dose injection of interleukin-6 on thyroid function in healthy humans. *Metabolism* 47: 1289–1293, **1998**
- Touyz RM, Chen X, Tabet F, Yao G, He G, Quinn MT, Pagano PJ, Schiffrin EL:** Expression of a functionally active gp91phox containing neutrophil-type NAD(P)H oxidase in smooth muscle cells from human resistance arteries: Regulation by angiotensin II. *Circ Res* 90: 1205–1213, **2002**
- Trivieri MG, Oudit GY, Sah R, Kerfant BG, Sun H, Gramolini AO, Pan Y, Wickenden AD, Croteau W, Morreale deEscobar G, Pekhletski R, St Germain D, MacLennan DH, Backx PH:** Cardiac-specific elevations in thyroid hormone enhance contractility and prevent pressure overload-induced cardiac dysfunction. *Proc Natl Acad Sci U S A* 103:6043–6048, **2006**
- Uday M. Khosla, Sergey Zharikov, Jennifer L. Finch, Takahiko Nakagawa, Carlos Roncal, Wei Mu, Karina Krotova, Edward R. Block, Sharma Prabhakar, and Richard J. Johnson.** Hyperuricemia induces endothelial dysfunction, *Kidney International*, Vol.67, pp.1739–1742 **2005**

- Valkonen VP, Paiva H, Salonen JT, Lakka TA, Lehtimäki T, Laakso J, Laaksonen R:** Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. *Lancet* 358:2127–2128, **2001**
- Vanholder R, De Smet R, Glorieux G et al.** Review on uremic toxins: classification, concentration, and inter individual variability. *Kidney Int* 63: 1934–1943, **2003**
- Vanholder R, Massy Z, Argiles A, Spasovski G, Verbeke F, Lamiere N:** Chronic kidney disease as a cause of cardiovascular morbidity and mortality. *Nephrol Dial Transpl* 20:1048–1056, **2005**
- Vasa M, Fichtlscherer S, Adler K, Aicher A, Martin H, Zeiher AM, Dimmeler S:** Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease. *Circulation* 103: 2885–2890, **2001**
- Vasile EM, Simionescu M, Simionescu N:** Visualisation of the binding, endocytosis and transcytosis of low density lipoprotein in arterial endothelium in situ. *J Cell Biol* 96:1677–1689, **1983**
- Vassalotti JA, Stevens LA, Levey AS:** Testing for chronic kidney disease: a position statement from the National Kidney Foundation. *Am J Kidney Dis* 50: 169–180, **2007**
- Venugopal SK, Devaraj S, Yuhanna I, et al.** Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. *Circulation*. 106:1439–1441, **2002**
- Verma S, Raj SR, Shewchuk L, et al.** Cyclooxygenase-2 blockade does not impair endothelial vasodilator function in healthy volunteers: randomized evaluation of rofecoxib versus naproxen on endothelium dependent vasodilatation. *Circulation*. 104:2879–2882, **2001**
- Verma S, Wang CH, Li SH, Dumont AS, Fedak PW, Badiwala MV, Dhillon B, Weisel RD, Li RK, Mickle DA, Stewart DJ:** A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. *Circulation* 106: 913–919, **2002**
- Verma S, Anderson TJ.** Fundamentals of endothelial function for the clinical cardiologist. *Circulation*. 105:546–549, **2002**

- Verma S, Kuliszewski MA, Mickle DAG, et al.** C-reactive protein attenuates endothelial progenitor cell survival and differentiation. *CanJ Cardiol.* 18(suppl B):325, 2002
- Verma S, Li SH, Badiwala MV, et al.** Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. *Circulation.* 105:1890–1896, 2002
- Verma, Michael R. Buchanan and Todd J. Anderson:** Endothelial Function Testing as a Biomarker of Vascular Disease. *Circulation* 108; 2054-2059, 2003
- Verma S, Li SH, Wang CH, et al.** Hyperglycemia potentiates the proatherogenic effects of C-reactive protein: reversal with rosiglitazone. *J Mol Cell Cardiol.* 35:417–419, 2003
- Virdis A, Ghiadoni L, Cardinal H, Favilla S, Duranti P, Birindelli R, Magagna A, Bernini G, Salvetti G, Taddei S, Salvetti A:** Mechanisms responsible for endothelial dysfunction induced by fasting hyperhomocystinemia in normotensive subjects and patients with essential hypertension. *J Am Coll Cardiol* 38: 1106–1115, 2001
- Virdis A, Iglarz M, Neves MF, Touyz RM, Rozen R, Schiffrin EL:** Effect of hyperhomocystinemia and hypertension on endothelial function in methylenetetrahydrofolate reductase-deficient mice. *Arterioscler Thromb Vasc Biol* 23: 1352–1357, 2003
- Vlachojannis J, Tsakas S, Petropoulou C, Kurz P:** Increased renal excretion of endothelin-1 in nephrotic patients. *NephrolDial Transplant* 12: 470–473, 1997
- Vriese AS, Tilton RG, Elger M, Stephan CC, Kriz W, Lameire NH:** Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes. *J Am SocNephrol* 12: 993–1000, 2001
- Wakino S, Hayashi K, Tatematsu S, Hasegawa K, Takamatsu I, Kanda T, Homma K, Yoshioka K, Sugano N, Saruta T.** Pioglitazone lowers systemic asymmetric dimethylarginine by inducing dimethylarginine dimethylaminohydrolase in rats. *Hypertens Res* 28: 255-62, 2005

- Wanby P, Brattstrom L, Brudin L, Hultberg B, Teerlink T:** Asymmetric dimethylarginine and total homocysteine in plasma after methionine loading. *Scand J Lab Invest* 63: 347–357, **2003**
- Wang JL, Cheng H-F, Shappell S, Harris RC:** A selective cyclooxygenase-2 inhibitor decreases proteinuria and retards progressive renal injury in rats. *Kidney Int* 57: 2334–2342, **2000**
- Wang CH, Li SH, Weisel RD, et al.** C-reactive protein upregulates angiotensin type 1 receptors in vascular smooth muscle. *Circulation*. 107:1783–1790, **2003**
- Wang TJ, Gona P, Larson MG, Tofler GH, Levy D, Newton-Cheh C, Jacques PF, Rifai N, Selhub J, Robins SJ, Benjamin EJ, D'Agostino R, Vasan RS:** Multiple biomarkers for the prediction of first major cardiovascular events and death. *N Engl J Med* 21: 2631–2639, **2006**
- Wang AY, Lam CW, Wang M, Woo J, Chan IH, Lui SF, Sanderson JE, Li PK:** Circulating soluble vascular cell adhesion molecule 1: Relationships with residual renal function, cardiac hypertrophy, and outcome of peritoneal dialysis patients. *Am J Kidney Dis* 45: 715–729, **2005**
- Wang AY, Lam CW, Wang M, Chan IH, Goggins WB, Yu CM, Lui SF, Sanderson JE:** Prognostic value of cardiac troponin T is independent of inflammation, residual renal function, and cardiac hypertrophy and dysfunction in peritoneal dialysis patients. *Clin Chem* 253: 882–889, **2007**
- Wang AY, Lam CW, Yu CM, Wang M, Chan IH, Zhang Y, Lui SF, Sanderson JE:** N-terminal pro-brain natriuretic peptide: an independent risk predictor of cardiovascular congestion, mortality, and adverse cardiovascular outcomes in chronic peritoneal dialysis patients. *J Am Soc Nephrol* 18:321–330, **2007**
- Wanner C, Krane V, Marz W, Olschewski M, Mann JF, Ruf G, Ritz E:** Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. *N Engl J Med* 353: 238–248, **2005**

- Webb DJ, Monge JC, Rabelink TJ, Yanagisawa M:** Endothelin: New discoveries and rapid progress in the clinic. *Trend Pharmacol Sci* 19: 5–8, **1998**
- Weissinger EM, Kaiser T, Meert N, De Smet R, Walden M, Mischak H, Vanholder RC: Proteomics:** A novel tool to unravel the pathophysiology of uraemia. *Nephrol Dial Transpl* 19: 3068–3077, **2004**
- Weissinger EM, Nguyen-Khoa T, Fumeron C, Saltiel C, Walden M, Kaiser T, Mischak H, Drueke TB, Lacour B, Massy ZA:** Effects of oral vitamin C supplementation in hemodialysis patients: A proteomic assessment. *Proteomics* 6: 993–1000, **2006**
- Wenzel RR, Mann J, Jurgens C, Yildirim I, Bruck H, Philipp T, Mitchell, A:** The ETA-selective antagonist SPP301 on top of standard treatment reduces urinary albumin excretion rate in patients with diabetic nephropathy [Abstract]. *J Am Soc Nephrol* 16: 58A, **2005**
- Wesson DE:** Endogenous endothelins mediate increased distal tubule acidification induced by dietary acid in rats. *J Clin Invest* 99: 2203–2211, **1997**
- Wesson DE:** Endogenous endothelins mediate increased acidification in remnant kidneys. *J Am Soc Nephrol* 12: 1826–1835, **2001**
- Westhuyzen J, Saltissi D, Healy H.** Oxidation of low density lipoprotein in hemodialysis patients: effect of dialysis and comparison with matched controls. *Atherosclerosis* 129: 199–205, **1997**
- Williams B, Baker A, Gallacher B, Lodwick D:** Angiotensin II increases vascular permeability factor gene expression by human vascular smooth muscle cells. *Hypertension* 25: 913–917, **1995**
- Williams SB, Goldfine AB, Timimi FK, Ting HH, Roddy MA, Simonson DC, Creager MA:** Acute hyperglycemia attenuates endothelium-dependent vasodilation in humans in vivo. *Circulation* 97: 1695–1701, **1998**

- Wolf SC, Brehm BR, Gaschler F, Brehm S, Klaussner M, Smykowski J, Amann K, Osswald H, Erley CM, Risler T:** Protective effects of endothelin antagonists in chronic renal failure. *Nephrol Dial Transplant* 14[Suppl 4]: 29–30, **1999**
- Wolf M, Shah A, Gutierrez O, Ankers E, Monroy M, Tamez H, Steele D, Chang Y, Camargo CA, Tonelli M, Thadhani R:** Vitamin D levels and early mortality among incident hemodialysis patients. *Kidney Int* 72: 1004–1013, **2007**
- Wu R, Lamontagne D, de Champlain J:** Antioxidative properties of acetylsalicylic Acid on vascular tissues from normotensive and spontaneously hypertensive rats. *Circulation* 105: 387–392, **2002**
- Xiao S, Wagner L, Schmidt RJ, Baylis C:** Circulating endothelial nitric oxide synthase inhibitory factor in some patients with chronic renal disease. *Kidney Int* 59: 1466–1472, **2001**
- Xu B, Chibber R, Ruggiero D, Kohner E, Ritter J, Ferro A:** Impairment of vascular endothelial nitric oxide synthase activity by advanced glycation end products. *FASEB J* 17:1289–1291, **2003**
- Yamada H, Sexton PM, Chai SY, Adam WR, Mendelsohn FA:** Angiotensin II receptors in the kidney. Localization and physiological significance. *Am J Hypertens* 3: 250–255, **1990**
- Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T:** A novel potent vasoconstrictor peptide produced by vascular endothelial cells. *Nature* 332: 411–415, **1988**
- Yevdokimova N, Wahab NA, Mason R:** Thrombospondin 1 is the key activator of TGF- β 1 in human mesangial cells exposed to high glucose. *J Am Soc Nephrol* 12: 703–712, **2001**
- Yilmaz MI, Saglam M, Caglar K, Cakir E, Sonmez A, Ozgurtas T, Aydin A, Eyileten T, Ozcan O, Acikel C, Tasar M, Genctoy G, Erbil K, Vural A, Zoccali C.** The determinants of endothelial dysfunction in CKD: oxidative stress and asymmetric dimethylarginine. *Am J Kidney Dis* 47: 42–50, **2006**

- Yilmaz MI, Saglam M, Caglar K et al.** The determinants of endothelial dysfunction in CKD: oxidative stress and asymmetric dimethylarginine. *Am J Kidney Dis* 47: 42–50, **2006**
- Yilmaz M, Saglam M, Carrero J et al.** Serum Visfatin concentration and endothelial dysfunction in chronic kidney disease. *Nephrol DialTransplant*. doi:10.1093/ndt/gfm727, **2007**
- Zaninotto M, Mion MM, Novello E, Altinier S, Plebani M:** New biochemical markers: From bench to bedside. *ClinChim Acta* 381: 14–20, **2007**
- Zannad F, Kessler M, Leheret P, Gruenfeld JP, Thuilliez C, Leizorovicz A, Lechat P:** Prevention of cardiovascular events in end-stage renal disease: Results of a randomized trial of foscinopril and implications for future studies. *KidneyInt* 70: 1318–1324, **2006**
- Zeher AM, Drexler H, Wollschlaeger H, et al.** Endothelial dysfunction of the coronary microvasculature is associated with impaired coronary blood flow regulation in patients with early atherosclerosis. *Circulation*. 84:1984–1992, **1991**
- Zeher AM, Drexler H, Wollschlager H, Just H:** Modulation of coronary vasomotor tone in humans. Progressive endothelial dysfunction with different early stages of coronary atherosclerosis. *Circulation* 83:391–401, **1991**
- Zeher AM, Krause T, Schachinger V, et al.** Impaired endothelium dependent vasodilation of coronary resistance vessels is associated with exercise-induced myocardial ischemia. *Circulation*. 91:2345–2352, **1995**
- Zhang X, Li H, Jin H, Ebin Z, Brodsky S, Goligorsky MS:** Effects of homocysteine on endothelial nitric oxide production. *Am J Physiol Renal Physiol* 279: F671–F678, **2000**
- Zhang L, Zalewski A, Liu Y, Mazurek T, Cowan S, Martin JL, Hofmann SM, Vlassara H, Shi Y:** Diabetes-induced oxidative stress and low-grade inflammation in porcine coronary arteries. *Circulation* 108: 472–478, **2003**

- Zhang L, Kao L, Berthier-Schaad Y, Plantinga L, Fink N, Smith MW, Coresh J:** C-reactive protein haplotype predicts serum C-reactive protein levels but not cardiovascular disease risk in a dialysis cohort. *Am J Kidney Dis* 49: 118–126, **2007**
- Zhang X, Li H, Jin H, Ebin Z, Brodsky S, Goligorsky MS:** Effects of homocysteine on endothelial nitric oxide production. *Am J Physiol Renal Physiol* 279: F671–F678, **2000**
- Zhang X, Jin H, Li H, et al:** Effects of homocysteine on nitric oxide production by endothelial cells. *Am J Physiol* 279:F671–F678, **2000**
- Ziche M, Morbidelli L, Choudhuri R, Zhang HT, Donnini S, Granger HJ, Bicknell R:** Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis. *J Clin Invest* 99:2625–2634, **1997**
- Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C:** Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. *Kidney Int* 55: 648–658, **1999**
- Zoccali C, Bode-Boger SM, Mallamaci F, Bendetto FA, Tripepi G, Malatino L, Cataliotti A, Bellanuova I, Fermo I, Frolich JC, Boger RH:** Plasma concentrations of asymmetrical dimethylarginine and mortality in patients with endstage renal disease: A prospective study. *Lancet* 358: 2113–2117, **2001**
- Zoccali C, Mallamaci F, Parlongo S, Cutrupi S, Benedetto A, Tripepi G, Bonanno G, Rapisarda F, Fatuzzo P, Seminara G, Cataliotti A, Stancanelli B, Malatino LS:** Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease. *Circulation* 105: 1354–1359, **2002**
- Zoccali C, Mallamaci F, Tripepi G et al.** Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. *J Am Soc Nephrol* 13: 134–141, **2002**
- Zoccali C, Mallamaci F, Tripepi G, Cutrupi S, Parlongo S, Malatino LS, Bonanno G, Rapiarda F, Fatuzzo P, Seminara G, Stancanelli B, Nicocia G, Buemi M:** Fibrinogen, mortality and incident cardiovascular complications in end-stagerenal failure. *J Intern Med* 254: 132–139, **2003**

- Zoccali C, Tripepi G, Cutrupi S, Pizzini P, Mallamaci:** Low triiodothyronine: A new facet of inflammation in end-stage renal disease. *J Am Soc Nephrol* 16: 2789-2795, **2005**
- Zoccali C, Mallamaci F, Tripepi G, Cutrupi S, Pizzini P:** Low triiodothyronine and survival in end-stage renal disease. *Kidney Int* 70: 523-528, **2006**
- Zoccali C, Testa A, Spoto B, Tripepi G, Mallamaci F:** Mendelian randomization: A new approach to studying epidemiology in ESRD. *Am J Kidney Dis* 47: 332-341, **2006**
- Zoccali C, Benedetto F, Mallamaci F, Tripepi G, Cutrupi P, Pizzini P, Malatino LS, Bonanno G, Seminara G:** Low triiodothyronine and cardiomyopathy in patients with end stage renal disease. *J Hypertens* 24: 2039-2046, **2006**
- Zoccali C.** Endothelial dysfunction and the kidney: emerging risk factors for renal insufficiency and cardiovascular outcomes in essential hypertension. *J Am Soc Nephrol* 17: S61-S63, **2006**
- Zoccali C, Maio R, Tripepi G, Mallamaci F, Perticone F.** Inflammation is the mediator of the link between mild to moderate renal insufficiency and endothelial dysfunction in essential hypertension. *J Am Soc Nephrol* 17: 64-8, **2006**
- Zoja C, Morigi M, Figliuzzi M, Bruzzi I, Oldroyd S, Benigni A, Ronco P, Remuzzi G:** Proximal tubular cell synthesis and secretion of endothelin-1 on challenge with albumin and other proteins. *Am J Kidney Dis* 26: 934-941, **1995**